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Clinical studies of patients with cystic fibrosis have documented 
considerable variability both in the constellations of symptoms present 
at diagnosis and in subsequent survival rates. No study to date has 
examined associations between clinical features apparent at presentation 
and subsequent outcomes defined in terms of morbidity as well as 
mortality. In the present study we have 1) characterized clinical 
features manifest by 89 patients upon enrollment in the Yale Cystic 
Fibrosis Clinic; 2) assessed with a clinical scoring system the status 
of each patient at enrollment and follow-up intervals of five and ten 
years; and 3) correlated clinical features at presentation with subse¬ 
quent clinical scores. Our data indicate that patients presenting with 
steatorrhea and no respiratory symptoms had favorable courses with just 
2 of 22 patients deteriorating substantially by five years. Meconium 
ileus was associated with a less favorable prognosis and the worst 
outcomes occurred in patients presenting with respiratory disease, with 
16 of 49 deteriorating after five years. The initial score and age at 
presentation had no bearing on subsequent outcomes. We conclude that 
clinical features apparent at diagnosis are valuable prognostic indica¬ 
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Cystic fibrosis (CF) is the most prevalent lethal genetic disease in 
America. Since the initial descriptions of CF in the late 1930's^ an 
extensive literature has been published on its genetic, biochemical, 
pathologic, and clinical features. Clinical studies have documented that 
patients with CF initially present with a variety of distinct constellations 
of symptoms.^ Studies have also established that the survival of patients 
with cystic fibrosis varies widely as well, with some patients dying in 
infancy and others living into their 301s.3 Few investigators have sought 
associations between particular presentations and subsequent survival; no 
study has examined relationships between clinical features at the time of 
diagnosis and subsequent outcomes measured in terms of morbidity, not 
mortality. The present study examines records of patients enrolled in the 
Cystic Fibrosis Clinic at Yale-New Haven Hospital, with the goal of 
discerning associations between clinical features at presentation and 
subsequent patterns of morbidity as well as mortality. In this introductory 
section, selected aspects of cystic fibrosis will be discussed to provide 
necessary background information for this study. More complete introductory 
discussions of the disease can be found in pediatric texts.^ 
General Features: In the United States, cystic fibrosis affects 
approximately one in every 2,000 live births among Caucasians and one in 
17,000 among Blacks^. Both sexes are affected equally.6 Neither the 
abnormal genetic locus (or loci) nor the fundamental biochemical lesion 
have been identified. Protean pathologic changes have been described, most 
due to excessively tenacious mucus secretions which block gland ducts and 
i ■' 
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acini.^ This process often results in the typical triad of chronic 
obstructive pulmonary disease (COPD), exocrine pancreatic insufficiency, 
and elevated concentrations of chloride in sweat^. Dozens of other clinical 
conditions frequently accompany cystic fibrosis, including nasal polyps, 
sinusitis, biliary cirrhosis, and aspermia.^ 
Diagnosis and Clinical Heterogeneity: The diagnosis of cystic fibrosis 
rests upon finding elevated sweat chloride (greater than 60 mEq/liter as 
determined by the pilocarpine iontophoresis method of Gibson et al.)® with 
evidence of one or more of the following: COPD, exocrine pancreatic 
insufficiency, or a positive family history.However, it has become 
increasingly clear that not all patients with CF present as prototypically 
wasted children with steatorrhea, chronic cough, and recurrent pneumonia. 
Several distinct clinical presentations have been recognized. These can 
be found in Table 1, as the classification of clinical presentations in 
cystic fibrosis adopted by the European Working Group for CF in 1976.^ It 
should be noted that rare patients are diagnosed on the basis of symptoms 
which are neither gastrointestinal nor respiratory, such as heat prostration 
with hyponatremia and hypochloremia, pansinusitis and aspermia.^ 
The presentation of cystic fibrosis is heterogeneous with respect to 
age as well as symptoms. Data from the Cystic Fibrosis Foundation Patient 
Registry reveal that among the 901 new diagnoses reported to the Foundation 
in 1979, 57% of patients were diagnosed by one year of age, 33% between one 
and 10 years, 6.5% between 10 and 20, and 3.5% after 20 years of age.^ 
Interestingly, comparison with analogous data from 1969 indicates 
substantial changes. Among patients diagnosed and reported in 1969, only 
47% of patients were diagnosed by one year of age, 40.7% between one and 

TABLE i 
Classification according to symptoms present at the 
time of diagnosis (adopted by the European Working 
Group for Cystic Fibrosis) 
I. Patients who came to diagnosis because of a positive family 
history. These comprised patients diagnosed at birth and 
those diagnosed later in life because of an affected sibling 
II. Predominantly gastrointestinal symptoms such as steatorrhea, 
rectal prolapse, abdominal pain, failure to thrive, 
avitaminosis. No clinical evidence of lung disease. 
III. Gastrointestinal and pulmonary symptoms. 
IV. Patients with predominantly pulmonary symptoms, including 
chronic cough, bronchitis, pneumonia, radiologic evidence of 
lung involvement. 
V. Meconium ilajjat birth requiring surgical treatment. 
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10 years, 10.9% between 10 and 20 years, and 1.4% after 20 years of age. 3 
Thus, over the nine year period increases were observed both in the 
proportion of patients diagnosed early in infancy and in the number diagnosed 
in adulthood. 
Several hypotheses can be offered to explain these changes. It is 
possible, for example, that the biological behavior of the disease could 
have changed over nine years. A more plausible explanation, accepted by 
most investigators, is that physicians have developed a heightened suspicion 
of cystic fibrosis. This would likely result in earlier recognition and 
diagnosis of active disease in infancy and more frequent recognition of 
adult cases that might have been missed by clinicians in earlier secular 
periods. It is important to note that patients diagnosed in adulthood enjoy 
a relatively good prognosis. Some investigators have suggested that these 
patients have a distinct mild variant of the disease, although this claim 
cannot be evaluated definitively by biochemical markers of severity or 
comparisons of genetic loci.^ One could also argue that increased suspicion 
of cystic fibrosis has shed light upon a wider spectrum of disease than 
previously appreciated. 
Treatment; Curative therapy does not exist for cystic fibrosis. 
Treatment is aimed toward preventing or eradicating specific disease 
symptoms and complications. In particular, clinicians attempt to maintain 
adequate nutritional status and to prevent the progression of pulmonary 
disease.Complications such as rectal prolapse, biliary cirrhosis, 
diabetes mellitus, cor pulmonale, and pneumothorax are managed as they would 
be for other patients. 
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Treatment of gastrointestinal disease is relatively straightforward 
and has changed little over the last three decades. The cornerstones of 
therapy include dietary management, pancreatic enzyme supplementation, and 
vitamin supplementation.10While enzyme preparations have been made more 
convenient, studies have not found newer enzyme preparations to be 
substantially more effective than their predecessors.11 
The treatment of respiratory disease is considerably more complex and 
controversial. Principal techniques include physical measures, aerosol 
therapy, and anti-microbial therapy. Most physicians strongly advocate 
chest physiotherapy, specifically percussion, postural drainage, and 
cough.^ However, there has been little objective documentation of efficacy 
for these procedures.2 Aerosol therapy rests on the assumption that 
hydration of tracheobronchial secretions will improve their rate of 
clearance f^om the lung and that administration of drugs by aerosol improves 
delivery to the tracheobronchial mucosa.2 Continuous mist tent therapy has 
been regarded with varying degrees of enthusiasm since its introduction in 
the 1940's.12 xts efficacy remains debatable, as studies of pulmonary 
function after nightly mist therapy have yielded conflicting results.12,13 
Intermittent aerosol therapy — intended to deliver antibiotics, 
bronchodilators, and mucolytics — has been used widely for over three 
decades. Again, controlled studies examining the efficacy of this treatment 
simply do not exist.2 
The last two paragraphs indicate that no major advances have occurred 
in the treatment of gastrointestinal disease or in chest physio- or aerosol 
therapy. In sharp contrast, antibiotic therapy has advanced dramatically 
over the last four decades. In cystic fibrosis, antibiotic therapy is 
- 
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’’’tended to control S. aureus, a frequent pathogen in infants and young 
children with CF, and P. aeruginosa, the highly virulent organism usually 
emerging as the predominant pathogen in bronchial secretions later in the 
course of disease.^ 
It is useful to distinguish four historical periods in the antimicrobial 
therapy of respiratory disease in cystic fibrosis.^>10 The first might 
be termed "pre-antibiotic" and ended with the introduction of penicillin 
in the early 1940's. The second era, lasting until 1948, was characterized 
by reasonable staphylococcal coverage with sulfa drugs and penicillin, but 
deficient treatment of pseudomonas. Tetracyclines ushered in the third 
era, during which many agents were developed providing good coverage of 
staph and moderate activity against pseudomonas. Finally, the introduction 
of gentamycin and semisynthetic penicillins in 1968 allowed much more 
effective treatment of pseudomonas for the first time. Recognition of these 
distinct treatment eras is critical to the design and interpretation of 
clinical studies because the secular period of diagnosis and treatment might 
be expected to affect outcome. This concept will be re-emphasized later 
in this study. 
Prognosis: Associations between distinct prognoses and such factors 
as sex, race, and presenting symptoms will be discussed in detail in the 
literature review. The present section will simply capsulize recent data 
on the range of prognoses in patients with cystic fibrosis and will highlight 
changes in these figures over the last decade. 
Survival data from the Cystic Fibrosis Foundation reveal the following 
findings:^ In 1978, 10% of patients under care were older than 20 years 
of age. Cross-sectional life table analysis of the 1978 data indicate that 
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the median age of survival was 21. Corresponding data from 1969 reveal 
that 10% of the patients under care were more than 16 years old and the 
median age of survival by cross-sectional life table analysis was 14.3. 
These results point toward two findings which have been corroborated by 
others as well.15,16 First, the prognosis for patients with cystic fibrosis 
is quite variable, with some patients dying in infancy, others surviving 
into their 30 1 s» Second, the median age of survival has improved 
substantially over the last decade. ^ Data do not exist to allow a 
determination of whether morbidity patterns over the past decade have 
paralleled those noted for mortality. 
Investigators have posited several explanations for the improvement 
in survival of patients with cystic fibrosis. First, the advances in 
antimicrobial therapy described above could account for better outcomes.2 
Also, the increasing number of patients diagnosed in adult years could have 
a distinct milder variant of the disease associated with a longer median 
survival age. The diagnosis of children at increasingly younger ages has 
allowed earlier treatment; some have claimed that earlier treatment leads 
to better prognosis. * While each of these arguments can be defended 
on intuitive grounds, they must be regarded as speculative as data do not 
exist to adequately evaluate the contribution of each of these factors to 
improvements in prognosis. 
Goals and Aims of the Study: It is clear from the preceding sections 
that patients with cystic fibrosis vary considerably in the particular 
symptoms manifest at the time of diagnosis. It is also apparent that the 
range of clinical outcomes varies widely among these patients as well. The 
overall goal of the present study is to determine whether particular 
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constellations of symptoms manifest at the time of diagnosis are associated 
with distinct clinical outcomes. 
The recognition of prognostically distinct subgroups of patients has 
important implications for clinical research and clinical practice. From 
a research standpoint, demographic studies and clinical trials of 
therapeutic interventions could be much improved by stratification of 
patients at the time of diagnosis into groups with distinct prognoses. 
Specific treatments may prove effective only in certain subgroups of patients 
and ineffective in others. Such subtle but crucial distinctions cannot be 
made presently. For the clinician, the ability to predict the approximate 
course of disease based on presenting symptoms would provide several 
advantages. First, clinicians could more meaningfully counse 1 patients and 
families as to the expected course of disease. Also, clinicians could more 
appropriately gauge the aggressiveness of their treatment and particular 
choices of intervention. 
In order to achieve the overall goal outlined above, the data collection 
and analysis in this study have been guided by five specific aims: (1) 
characterization of the basic demographic features of the patients followed 
at the Yale-New Haven Cystic Fibrosis Clinic; (2) characterization of the 
baseline clinical status of each patient at the time of enrollment into the 
clinic, including historical data, symptoms, and signs. It is important 
to realize that except for the rare patient diagnosed after seven years of 
age, patients with cystic fibrosis are too young at the time of presentation 
to perform pulmonary function tests. Hence, baseline clinical 
characteristics cannot include PFT's, which have become the parameters of 
choice for following the progress of older patients; (3) numerical assessment 
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of the clinical status of each patient at enrollment and at follow-up 
intervals; (4) correlation of particular clinical features present upon 
enrollment with subsequent numerical assessment of outcome at five and ten 
year follow-up; and (5) correlation of clinical features of presentation 
with changes in outcome scores over five and ten year intervals. The methods 




I. Clinical Setting 
The Yale-New Haven Cystic Fibrosis Center was established decades ago. 
However, detailed files of clinic notes have only been maintained since 
1966 and the present clinic director has worked in the clinic since 1970. 
Funding is received primarily (60%) from Yale University with additional 
upp-rt .rom state allocation and a Cystic Fibrosis Foundation Grant.^ 
The clinic personnel include the director — a professor of pediatrics at 
Yale University with clinical and basic science research interests in cystic 
fibrosis; an associate physician director; a clinic laboratory technician 
(for sweat tests and pulmonary function tests); a social worker from the 
Department of Pediatrics; and a clinic secretary. In addition, Yale-New 
Haven Hospital pediatric housestaff and Yale medical students have the 
opportunity to rotate through the clinic. 
Clinic is held twice weekly in the pediatric specialty clinics area 
of the hospital. All patients are urged to schedule at least four visits 
per year. Sicker patients are scheduled more often. While most younger 
patients and their families are quite compliant, young adults attend clinic 
less frequently, often yearly. At each clinic visit, patients are 
typically first seen by a nurse who obtains and records vital signs and 
anthropometric measurements. In addition, sputum cultures, chest x-rays, 
and pulmonary function tests are obtained at regular intervals. Presently, 
chest films are taken yearly and pulmonary function tests (for patients 
over seven years of age) are performed twice a year. Throat cultures are 
taken at each visit. These guidelines vary considerably with the severity 
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of the patient's illness. After routine testing, the patients are seen 
first by medical students and/or residents and then by the attending 
physician. Except for rare occasions, the clinic director sees every 
patient. Pertinent historical and physical findings are recorded (usually 
by the resident or student) on a prepared form. Hence, there is uniformity 
in the scope and quality of data obtained at each visit. 
For each visit the clinic director dictates a note which includes 
pertinent historical, physical, and laboratory findings and changes in 
therapy. The note is based both on the director's assessment and the 
information recorded by other observers. Notes, laboratory result sheets, 
and hospital discharge summaries for each patient are entered into 
longitudinal files located in the director's office. 
II. Population Studied 
Patients seen in the Yale Cystic Fibrosis Clinic live throughout 
Connecticut, mostly in the southern part of the state. The patients 
represent a wide range of socioeconomic backgrounds. Patients are referred 
to the clinic through a variety of mechanisms: Often, a local practitioner 
who strongly suspects the diagnosis of cystic fibrosis sends the patient 
to Yale for definitive sweat testing and longitudinal care. Many patients 
have had positive sweat tests in work-ups at outlying hospitals and are 
subsequently referred for follow-up in the Yale clinic. Other patients are 
referred to Yale specialists for work-up of problems not initially felt to 
be cystic fibrosis. The Yale clinician might then order a sweat test or do 
so after consulting with the cystic fibrosis clinic team. Other referrals 
from within the institution include patients sweat tested during in-patient 
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work-ups, and patients referred from the Primary Care Center and the Neonatal 
Intensive Care Unit with presumptive diagnoses of cystic fibrosiso 
Three groups of patients with cystic fibrosis are not routinely referred 
to the Yale clinic. One is comprised of three patients who were either 
newly diagnosed or referred to the medical center in their adult years. 
These patients are followed by the Pulmonary Service of the Department of 
Medicine in Yale's Winchester Chest Clinic. Another group not seen in the 
cystic fibrosis clinic is comprised of patients managed by their local 
pediatricians. The number of these patients is difficult to determine, but 
is estimated at less than 3% of patients with the diagnosis of cystic 
fibrosis who live in areas served by the Yale clinic. ^0 The third group 
includes patients who die before they are able to enroll. These patients 
all have meconium ileus at birth and die within a few days. They comprise 
25% of patients with meconium ileus at Yale and 4-5% of all patients known 
to have cystic fibrosis.21 
III. Eligibility Criteria 
Patients who enrolled in the Yale-New Haven Cystic Fibrosis Clinic 
during the interval 1966 through 1978 were eligible for the study. This 
secular interval was chosen for several reasons. Exclusion of patients 
enrolled before 1966 assured that the course of each patient could be 
followed in the longitudinal record system which was established in 1966. 
In addition, the antipseudomonal antibiotics developed after 1968 were 
available to each patient. (Note that although eight patients were enrolled 
in 1966-1967, pseudomonas colonization usually does not occur until after 
age five.)22 Exclusion of patients enrolled after 1978 assured that all 
patients were followed for at least five years or until their deaths. 
✓ 
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Finally, patients who were followed in another clinic before enrollment in 
the Yale clinic were excluded from the study. This criteria assured that 
all data were obtained and recorded in the Yale clinic. 
IV. Diagnostic Criteria 
Criteria for the diagnosis of cystic fibrosis include sweat chloride 
levels greater than 60mg (by the pilocarpine iontophoresis method of Gibson 
et al.)® and at least one of the following: a) chronic obstructive pulmonary 
disease; b) exocrine pancreatic insufficiency; or c) positive family 
history. These diagnostic criteria have been employed at Yale throughout 
the time of this study and are widely accepted in the pediatric literature.^ 
V. Patients Who Left the Clinic 
Eight patients who were eligible for the study left the Yale clinic 
subsequent to enrollment. In each case, the patients departed because their 
families moved out of the area. In all but one of these patients, adequate 
assessment of clinical status at appropriate follow-up intervals was 
obtained by contacting physicians at the clinic to which the patients were 
transferred. 
VI. Zero Time 
The term "zero time" refers to the reference point in patients clinical 
courses at which the baseline state is identified and classified, and from 
which subsequent follow-up periods begin. We considered three possible 
zero times in this study: The time of diagnosis of cystic fibrosis; the 
time at which therapy was initiated; and the time of enrollment into the 
Yale clinic. The quality of information submitted by referring physicians 
who made the diagnosis of cystic fibrosis was highly variable. Some 
physicians submitted detailed notes listing signs and symptoms. Others 
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wrote just a sentence or two. Similarly, there was considerable variation 
in therapies prescribed by referring physicians prior to enrollment. Hence, 
in order to standardize both the data base and the medical interventions 
for all patients in the cohort, the time of enrollment into the clinic was 
chosen as the zero time. This choice guarantees that all data used in the 
study was obtained by the small clinic team and that all therapy initiated 
during the intervals studied was prescribed by the clinic team. We were 
concerned initially that the interval between diagnosis and enrollment would 
be considerable; however, review of the data revealed this interval usually 
was less than three weeks and always less than three months. 
VII. Sources of Data 
Three sources of data were utilized: Notes maintained by the clinic 
director, chest x-rays, and hospital discharge summaries. The clinic notes 
provided the bulk of information on features of the initial presentation 
and on subsequent outcomes. The content of these longitudinal notes was 
discussed earlier in this chapter. Chest x-rays were obtained from the 
Department of Diagnostic Imaging at Yale. Over 95% of the films requested 
were available for review. (The few remaining films were scored by the 
clinic director on the basis of official readings transcribed by the 
Department of Diagnostic Imaging.) Hospital discharge summaries were 
routinely placed in patients' files after discharge. 
VIII. Data Gathering 
Data were assembled in two separate steps: (1) extraction of 
information from the files onto prepared extraction forms; and (2) coding 
of pertinent information for computer analysis. Copies of both the 
extraction form and the coding form have been included as Appendices A and B. 
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Extraction was performed in the Spring of 1983 on a form designed to 
record all information pertinent to the basic goals of the study. The 
extraction form consisted of five section: (1) demographic information 
including name, address, gender, date of birth and enrollment, and parents' 
occupations; (2) pre-existing conditions such as family history of cystic 
fibrosis and co-morbidity; (3) a clinical itinerary of the principal illness 
consisting of a chronology of signs and symptoms attributable to cystic 
fibrosis, hospitalizations before and after diagnosis, signal events raising 
the suspicion of the diagnosis, and a chronological record of birth weights 
and percentiles; (4) appearance of specific signs and symptoms including a 
lengthy check list of findings derived from textbook descriptions of the 
disease. We included a category for "other" findings not on the list; and 
(5) follow-up data including the data of death and loss to follow-up. 
Several specific items on the coding form required precise defining 
criteria, as follows: In section one, "premature birth" was restricted to 
babies born more than four weeks before the expected date of confinement. 
In section two, "signal events" included data which, in the documented 
opinion of the physician who made the diagnosis, raised a strong suspicion 
of the diagnosis of cystic fibrosis. In section three, clubbing was recorded 
as "mild" if there was nailbed erythema without actual change in the angle 
between nail and nailbed. "Moderate" and "severe" referred to gradations 
in swelling with "severe" indicating obliteration of the angle. "Cor 
pulmonale" was a clinical diagnosis made on the basis of typical physical 
findings but usually without the confirmation of catheterization data. 
"Meconium plug syndrome" referred to abdominal pain which was accompanied 
by a mass consistent with fecal impaction in the cecum or terminal ileum. 

16 
"Steatorrhea" was defined by the patients' report of bulky, foul-smelling 
stools without measurement of fecal fat. "Vitamin deficiency" was similarly 
defined clinically without serum levels. "Hypoproteinemia" and "biliary 
cirrhosis" were defined by both characteristic laboratory values as well 
as physical findings. The intervals between birth and the onset of symptoms 
were gleaned from historical information offered by patients and families 
at the first clinic visit. The accuracy of this data clearly relies upon 
the patients' and families' ability to recall correctly the onset of 
symptoms. Recall of early symptoms can, of course, be biased by the knowledge 
of this ultimate diagnosis. 
Once extracted, most data was then transferred to coding forms for 
computer analysis. Two types of extracted data were not coded: The first 
includes data which were not reported consistently or were reported in vague 
terms for a substantial number of patients. An example of such "poor 
quality" data is the date of the initial suspicion of the diagnosis. This 
information turned out to be available for less than half of the patients. 
A second category of data not coded was information ultimately felt not to 
be helpful in realizing the goals of the study. Examples would include the 
dates of appearance of particular symptoms for patients in whom the symptoms 
occurred after zero time. Though potentially interesting, this post-zero 
time data was not felt to be critical to a study of relationships between 
zero time features and subsequent outcomes. In addition, a few items of 
data which were not initially extracted onto the prepared form were 
ultimately gleaned and coded. These included patients' height and the 
percentile values of height-for-weight and height-for-age. Percentiles 
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were obtained from standard charts prepared by the National Center for 
Health Statistics. 
IX. Assessment of Outcomes 
A. Outcome Measure 
Outcomes were assessed in terms of morbidity. While most previous 
work has examined survival only, it was felt that analysis of morbidity 
might detect clinical changes which are crucial to management decisions yet 
which could not be appreciated by assessment of mortality. The Shwachman 
scoring system was used to assess morbidity. Developed in 1958 by Harry 
Shwachman et al.^ this system of clinical evaluation assigns point ratings 
for each of four clinical attributes: Level of general activity (e.g., 
school attendance, vigor of play, fatigue); physical examination (cough, 
rales, clubbing); nutrition (height vs. weight, stool appearance, muscle 
mass); and x-ray findings (atelctasis, emphyema, infiltrates). For each 
attribute, 0-25 points are awarded, with 25 being normal. The scores are 
summed to a composite figure from 0-100 which reflects overall clinical 
status. Occasionally criticized as under-emphasizing pulmonary aspects, 
the Shwachman system is generally regarded as a reasonably objective, 
consistent, and pragmatic means of assessing clinical status in cystic 
fibrosis. The system is summarized in Appendix C. 
The present study employed a common modification of the Shwachman x- 
ray scoring system. The Shwachman system for chest radiographs does not 
carefully prescribe the designation of point values and has not proven to 
be reproducible among different observers.23 Many investigators have 
preferred to use the Brasfield scoring system, which has more explicitly 
stated scoring criteria and is documented to be reproducible.23 The 
. 
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Brasfield system (a description of which is included as Appendix D) assigns 
a maximum of five points in five categories: Air trapping, linear densities, 
nodular cystic lesions, large lesions, and overall assessment. 
Conveniently, it is also based on a maximum score of 25 points and can 
simply be substituted into the Shwachman score. 
B. Frequency of Assessment 
The clinical status of all patients entered into the study was assessed 
by modified Shwachman scoring at the time of enrollment and again after 
five years of follow-up. In addition, the 55 patients enrolled before 1974 
were included in an analysis of ten year follow-up as well. It was felt 
that these intervals would provide meaningful time frames for predicting 
prognoses. 
C. Clinical Categories 
Five categories of scores were established based on the advice of 
several pediatricians, including the clinic director: 90-100 (considered 
excellent); 80-89 (good); 70-79 (fair); 50-69 (poor); and less than 50 
(terminal). The categories correspond both to distinct levels of severity 
of disease and to distinctive management strategies. Patients with 
"excellent" scores were barely distinguishable from individuals without 
cystic fibrosis and required only routine check-ups. Patients in the "good" 
category suffered minor impairments and demanded occasional therapeutic 
intervention for acute exacerbations. "Fair" patients also had only minor 
compromise, but required more careful observation, occasional 
hospitalization, and more frequent therapeutic intervention. Patients in 
the "poor" category suffered significant morbidity, required 
hospitalization as often as bi-annually, and were seen in clinic every few 
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weeks. "Terminal” patients frequently used home oxygen therapy, contacted 
the clinic regularly because of acute exacerbations, were admitted several 
times each year to the hospital, and were in imminent danger of dying. 
D. Changes in Clinical Category 
Several clinicians including the clinic director advised us that in 
addition to the single state measurements of clinical status provided by 
the Shwachraan score and clinical category, it would also be valuable to 
assess clinically meaningful transitions in clinical states. In particular, 
it would be important to appreciate transitions which required changes in 
clinical management. We accounted for such transitions by describing 
patients' courses as "stable" if the patients either remained in the same 
clinical category or improved over the interval studied, and "deteriorating" 
if the patients slipped into a lower clinical category. Because the clinical 
categories are distinguished by unique management strategies, the changes 
in category by definition required changes in management. Thus, changes 
in category are of central concern to clinicians. Assessments of change 
in clinical category were determined by comparing five year to zero time 
clinical categories for all 89 patients, and ten year to zero time categories 
for the 55 patients followed for ten years. 
E. Process of E aluating Outcomes 
The clinic director assigned Shwachman scores based upon data contained 
in the clinic notes. The director was blind to the goals of the study. 
The clinic director also scored the chest x-rays. It was felt that the 
most accurate and consistent scoring could be obtained from a single observer 




F. Statistical Techniques 
Univariate contingency tables were used to identify features of the 
initial presentation which corresponded with distinct outcomes. The 
relative importance and interactions of the characteristics identified in 
the univariate analysis were then assessed in a multivariate analysis. 





This section will review the few published studies of patients with 
cystic fibrosis which address the fundamental goal of the present study: 
The search for relationships between clearly defined clinical features 
present at the time of diagnosis and subsequent clinical outcomes. Features 
examined by the authors whose works are reviewed include demographic data 
such as gender, race, age, and the secular period of diagnosis; objective 
measures of the extent of disease, such as chest x-ray and fecal fat content; 
and clinical symptoms, expressed as the presence or absence of particular 
organ system involvement. The outcome parameters in most of the studies to 
be reviewed consist of survival data. Only a few authors have assessed 
morbidity as well as mortality. 
This review is intended to aid in the design of the present study in 
two ways. First, it is important to evaluate previously documented 
relationships between presenting features and subsequent outcomes. These 
findings, if validly reached and corroborated, can be incorporated into 
model hypotheses. Second, it is useful to appreciate methodologic problems 
that have plagued previous studies. Once recognized, the pitfalls can more 
easily be avoided. In accordance with these two goals, the criticism shall 
be directed toward assessing the validity of findings which might guide the 
design of the present study and toward identifying methodologic problems 
that can then be minimized. 
This literature review will include papers on each of the demographic 
and clinical features of presentation which investigators have related to 
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subsequent outcomes. For the few areas in which more than one paper has 
been written, just one will be discussed in detail and discrepant findings 
of other works (if such exist) will be mentioned. Tables I and II summarize 
principal design features and findings of the studies reviewed. Note that 
five and ten year outcomes have been inferred from the data whenever 
possible. This information will be useful in comparing results of the 
present study in which outcomes are assessed at five and ten year intervals. 
II. Influence of Demographic Factors on Prognosis 
A. Gender 
Several investigators^ have analyzed the role of gender in 
predicting prognosis. The results of each study are consistent with those 
of Stern et al.^5 whose work shall be reviewed critically. The Stern group 
reported in 1976 on 95 patients who had been followed at the Case Western 
Clinic since their diagnoses in 1957-1961. Seven patients initially included 
in the cohort were lost to follow-up and consequently excluded from the 
analysis. Follow-up ranged from 13-17 years. The authors did not specify 
precisely how many patients of each sex were entered into the trial, nor 
did they comment upon the symptoms present or the age of each gender group 
at the time of diagnosis. Twenty-eight patients died, 16 of them females. 
Life table analysis of survival was performed through 17 years of follow¬ 
up. The authors generated curves plotting percentage survival vs. the 
number of years after diagnosis. These curves reveal that at five and ten 
years, the percentage of females surviving was actually higher than of 
males: 95% vs. 88% at five years and 85% vs. 78% at ten. However, at 16 
years of follow-up, the survival curves indicate a male survival of 78% 
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observation, made by several others^that survival among females 
deteriorates in the teenage years. The results would be much stronger if 
the authors had considered the age of diagnosis and the presenting symptoms 
in each gender group. Also, the survival curves have diminished statistical 
reliability at 16 years of follow-up because some patients were followed 
for less than 16 years. We are not informed of the number of patients 
followed 16 years, but are told that the minimum follow-up was 13 years and 
maximum 17 years. 
B. Race 
Race is seldom considered in studies of cystic fibrosis as 97.2% of 
diagnosed and reported patients in the U.S. are white^. In 1976, Stern et 
al.^ of Case Western compared 17 black patients diagnosed between 1957 and 
1974 with 93 white controls diagnosed between 1957 and 1961. The mean age 
at diagnosis was two years seven months for the black patients and was not 
given for the whites. Presenting symptoms were not mentioned. Forty-five 
percent of the blacks were male while the sex ratio in controls was not 
given. Follow-up duration differed markedly in the two groups: 2-17 years 
among the blacks; 15-17 years among the controls. Only one of the blacks 
and 28 of the controls died. Life table analysis generated survival curves 
which indicated that five year survival for both whites and blacks was 
around 95%. However, at ten years of follow-up, the survival of whites was 
80% while that of blacks remained around 95%. The authors concluded that 
the course of cystic fibrosis in blacks is milder than in whites. 
These conclusions simply cannot be accepted because of methodological 
problems. First, the secular period of entry into the study differs 
markedly. Blacks were entered as late as the mid 1970's while all whites 
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were diagnosed and entered in the late 1950's, As was described in the 
introductory chapter, antibiotic treatment and diagnostic acumen likely 
improved over three years; hence, one cannot exclude the possibility that 
differences in treatment and diagnosis of milder variants accounted for the 
results in this study, rather than race. The second problem, also severe, 
concerns the use of life table analysis in a group of only 17 patients, 
with only one death, followed for as short a time as two years in some 
cases. With numerator and denominators so small, the potential for 
misleading estimates is quite large. 
C» Secular Period of Diagnosis 
The issue of the secular period of diagnosis, central to the preceding 
study, was examined directly by Huang et al» of Temple in 1970.26 The 
authors identified three distinct secular periods in the treatment of 
patients with cystic fibrosis at St. Christopher's Hospital for Children. 
Prior to 1957 patients were treated with pancreatic enzymes and intermittent 
antibiotics, but without sustained intensive follow-up. In 1957, a cystic 
fibrosis clinic was established at St. Christopher's to provide close follow¬ 
up and long-term antibiotic therapy. In addition, the use of aerosol 
medication was introduced around 1957. In 1962, the clinic funding was 
bolstered and a more intensive program was developed including mist tent 
therapy, physical therapy, and improved dietary management. The Huang group 
hypothesized that treatment improved over these successive intervals, 
resulting in enhanced long-term survival. 
The authors sought to test this hypothesis. They examined mortality 
data of three cohorts of patients: (I) 37 patients admitted for treatment 
between 1952 and 1957. Twenty-four of the 37 were male and 60% were diagnosed 
• 
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before age one; (II) 73 patients admitted to the St. Christopher's clinic 
between 1957 and 1962. Thirty-seven (49%) of these were male and 38% were 
diagnosed before age one; (III) 129 patients diagnosed between 1962-1967. 
Forty-eight of these were male (39%) and 39% were diagnosed before age one. 
Of note, the authors do not specify the interval between diagnosis and 
admission for treatment. They also provide no information on the number 
of patients lost to follow-up. They do divide the patients into two clearly 
defined groups based on the severity of pulmonary involvement at first 
observation ("mild to moderate" and "severe"). This determination is based 
on history, physical exam, and x-ray. The authors do not provide the precise 
criteria used for the division. 
Life table analysis revealed that after five years of follow-up survival 
in group (i) was 35% (+ 8.9); group (II) survival was 63.6% (+ 6.4); and 
in group (III) 70.6% (+ 7.0). Groups (II) and (III) were analyzed further 
by stratifying according to age at diagnosis, sex, and severity of pulmonary 
disease. No explanation is given for the exclusion of group (I) from these 
analyses, although it seems likely that there were insufficient patients 
in the cohort for meaningful subdivision. Patients with "mild to moderate" 
lung disease at presentation had much better five year survivals than 
patients with "severe" lung involvement, 88.4% vs. 35.0% in group (II); 
92.6% vs. 21.2% in group (III). The clinical criteria for these categories 
are not given. The difference in survival between children first observed 
at less than one year was not statistically different from those admitted 
to the clinic after one year of age (61.5% vs. 67.5% in group (II); 79.8% 
vs. 73.8% in group (III)). Analysis of sex distribution revealed that in 
group (II) five year survival of females was better than males (74% vs. 
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44%) while in group (III) the males had better survival (82.4% vs. 69.5%) 
though the difference was not statistically significant (P > .05). Huang 
et al. interpret their data to indicate primarily that patients treated in 
the later secular intervals had better outcomes. They also conclude that 
extensive pulmonary disease at presentation is a poor prognostic indicator. 
The primary conclusion — that patients who enrolled in later years 
fared better — is difficult to evaluate because group (I) was not stratified 
according to sex and age at diagnosis. This is particularly important 
because the sex ratio and ages of patients in group (l) are so markedly 
different from those in the other patient groups. The poor five year 
survival of males in group (II) (44%) raises the question of whether outcomes 
in the predominantly male group (I) can be explained on the basis of sex, 
not secular period. The study would also be more meaningful if the 
chronological relation between diagnosis and entry into the study were 
clarified. Furthermore, survival data, while important, do not detect 
crucial changes in clinical status. Clinicians make management decisions 
based on morbid events. Hence, assessment of outcomes in terms of morbidity 
would be more valuable for clinicians than mortality data alone. As a 
result of these criticisms, conclusions must be tentative: The study 
indicates that the secular period of entry into the clinic must be 
scrutinized for its potential effect upon five year survival. 
D. Age of Diagnosis 
While the Huang group's cursory analysis of the age at diagnosis 
provided no definitive information it suggested that the age at diagnosis 
had no predictive prognostic value. diSantagnese et al.27 (1979) Gf the 
National Institutes of Health (NIH) attempted a more complete evaluation 
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of this relationship* The group studied 75 patients over 18 years of age 
followed at the NIH clinic. Fifty-five percent of the group was male and 
21% were diagnosed after age 15. Presenting symptoms were not mentioned. 
Of crucial importance , the patients studied comprise a residue cohort 
admitted to the clinic at age 18 rather than an inception cohort followed 
since diagnosis. Correlation of age at diagnosis with Shwachman scores in 
1979 (after a variable period of follow-up) revealed a correlation 
coefficient of -0.01 at a P value of 0.49. The authors conclude that the 
age of diagnosis is not correlated with clinical score. For the present 
study, these results and conclusions have negligible value. The relationship 
between information available at presentation and subsequent outcome cannot 
be studied in a residue cohort because many patients could have died or 
been lost to follow-up and were overlooked in the analysis. Hence, a 
reliable study of the relationship between the age at presentation and 
subsequent outcome remains to be completed. 
E. Comparison with Siblings 
In a study purported to demonstrate the effect of early diagnosis and 
treatment on clinical outcomes in cystic fibrosis, Orenstein et a 1.( 1977) 
studied 16 sibling pairs in their Case Western clinic. The 32 patients 
were diagnosed between 1957 and 1970. To qualify for the study, the older 
siblings must have been diagnosed after age one and the younger siblings 
before age one. Fifteen of the 16 older siblings and nine of the younger 
siblings had pulmonary disease at diagnosis. Fifty percent of the older 
siblings were male as were 44% of the younger siblings. No patients died 
and each was followed until age seven, the endpoint of the study. 
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Comparison between siblings was made using various outcome measures 
at age seven. These included chest x-rays, Shwachinan scores, pulmonary 
function tests (PFT's), and anthropometric measures. Data were analyzed 
using the paired student's t-test, with ordered pairs being (older sibling 
- mean/mean of the two siblings, younger sibling - mean/mean). The authors 
concluded that the younger siblings had better total scores than the older 
siblings (P < 0.05). Twelve of the younger siblings had higher scores at 
age seven. Average score for the 16 older siblings was 70 and for the 
younger siblings was 86. The younger siblings also had lower residual 
volumes and RV/TLC ratios (P < 0.05). In these categories, the younger 
sibling's score was better in 12 and 11 of the 16 pairs, respectively. 
Eleven of the younger siblings also had higher chest x-ray scores (Shwachman 
scores). Seven of the older siblings had chest x-rays of 16 or below compared 
with none of the younger siblings. The authors concluded that the younger 
siblings fared better and inferred that early diagnosis and treatment leads 
to better clinical outcomes. 
While these results indicate that younger siblings had better clinical 
outcomes in this study, inferences about the effect of early diagnosis and 
treatment simply cannot be made for several reasons. First, pairs in which 
the older sibling was diagnosed before age one were excluded from the study. 
This exclusion eliminates patients whose natural histories might have 
differed markedly from the older siblings studied. Of course, if the natural 
course of disease were identical between siblings, as the authors assume, 
this exclusion would not bias the results. But there is simply no evidence 
to suggest that in siblings the natural course of cystic fibrosis is 
identical or even similar.28 The authors failed to bolster their assumption 
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of homogeneity among siblings with comparisons of symptoms at presentation 
and later in the course. To conclude, the effect of early diagnosis on 
prognosis simply cannot be addressed by a study of sibling pairs. 
III. The Relationship Between Clinical Data Obtained at Diagnosis and 
Subsequent Outcomes 
A. Normal Pancreatic Function 
Only a few investigators have studied the relationships between either 
physiologic measure of disease or symptom status at diagnosis and subsequent 
clinical outcomes. Gaskin et al.^4 (1979) retrospectively examined 72 
patients diagnosed between 1962 and 1980 having normal pancreatic function 
as determined by fecal fat excretion. This group was compared with an 
unspecified number of patients with steatorrhea who were enrolled in the 
clinic at the time of the study. The 72 patients with normal fecal fat 
excretion consisted of 42 males and had a mean age at diagnosis of five 
years. All patients in the study were at least seven years old at the time 
of analysis — the age at which pulmonary function studies are first 
performed. The sex ratio of the controls was not given nor was the age at 
diagnosis nor mode of presentation. Interestingly, some of the patients 
with normal fecal fat excretion presented with loose stools. 
The authors compared PFT's (FEV^, FEV25-75, RV/TLC) arterial blood 
gases and the percentage of ideal weight for height among patients in four 
groups defined by presence or absence of steatorrhea and by sex. Data were 
obtained at six month intervals after age seven and plotted against patients' 
ages. Least squares regression lines were generated for the four groups 
for each of the clinical variables studied. Differences in slopes were 
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normal pancreatic function did better than controls in each of the categories 
studied. Among patients with steatorrhea, girls did worse than boys, the 
differences becoming apparent at around 15 years. For example, the 
regression for FEVj revealed that at ten years males and females with normal 
pancreatic function had values of around 95% of normal while males and 
females with steatorrhea had values around 85% of normal. However, the 
regression lines at 25 years of age showed males and females with normal 
pancreatic function hovering around 90% while males with steatorrhea had 
FEV| of 60% and females 40% of normal. 
The study, while fascinating, is quite problematic. First, cases have 
been entered over the secular period 1962-1980, which spans different eras 
in the treatment of cystic fibrosis. This tactic was criticized earlier 
in this review. Also, it would be extremely important to learn the average 
age at diagnosis of the patients with steatorrhea. Given the relatively 
late age of diagnosis of patients with normal fat excretion (five years), 
one wonders whether age of presentation might be an even stronger predictor 
of pulmonary function than pancreatic function. In addition, neither group 
is an inception cohort of patients diagnosed and then followed; rather they 
are residue cohorts of patients available for PFT's after age seven. Hence, 
information is lacking as to how many patients died before age seven or 
were lost to follow-up. 
Finally, the statistical methods are questionable. The regression 
lines are displayed extending from ages seven to thirty. However, it is 
not clear how many, if any, patients lived to age 30. The authors do not 
even compare the present ages or average lengths of follow-up in each group. 
Most important, they present no evidence that changes in pulmonary function 
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studies vary linearly with age in cystic fibrosis. The assumption of 
linearity is central both to the impressive graphic results and to the 
numerical calculations. To summarize, the authors present an interesting 
subgroup of patients clearly defined at diagnosis by laboratory measurement 
of fecal fat. They claim that this group enjoys better subsequent pulmonary 
function than age-matched controls, but unproved assumptions underlie their 
arguments. 
Bo Chest X-Ray Scores 
The prognostic value of initial chest x-ray scores was evaluated by 
Stern et al.^5 (1976) in a study of 102 patients admitted to the Case Western 
Clinic between 1957 and 1961. Seven patients were lost to follow-up and 
were not included in the analysis. Twenty-eight died and 67 continued to 
be followed at the time of publication. The patients were divided into two 
groups based on their highest chest x-ray scores over the first year of 
follow-up. This strategy was designed to distinguish between acute 
reversible findings at presentation and chronic lesions that persisted for 
a year. The authors fail to indicate the frequency with which chest x-rays 
were obtained during the first year of follow-up. Group (I) consisted of 
patients with at least one chest x-ray score greater than or equal to 19 
during the first year. (The Shwachman scoring system was used, with a 
maximum score of 25 points.) Patients in group (II) had first year scores 
consistently below 19. The sex distribution in the group is not given nor 
is the nature of clinical presentation. Age at diagnosis among patients 
in group (I) averaged 20 months for males and 38 months for females. In 
group (II), males were diagnosed at an average age of 102 months and females 
at 60 months of age. 
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Survival curves were calculated using life table analysis. 
Interpretation of the curves reveals that five year survival was around 98% 
for group (I) and 60% for group (II). Ten year survival in group (I) was 
around 95% and in group (II) 60%, The authors concluded that the presence 
of irreversible pulmonary disease predicts poor long-term prognosis. 
While the data strongly suggest that persistent x-ray abnormalities 
bode a poor prognosis, the analysis is not thorough enough to implicate 
irreversible pulmonary disease as the culpable factor. The patients should 
have been stratified by sex, a variable known to influence prognosis. In 
addition, the widely discrepant ages at diagnosis of patients in the two 
groups raise the question of whether age is the factor with most predictive 
power. The chest x-ray score could simply serve as a surrogate reflection 
of patients' ages at diagnosis rather than as an independent measure of the 
severity of pulmonary disease. Again, further analysis would be required 
to resolve this issue. Finally, as has been mentioned already in this 
review, survival data provide an incomplete assessment of clinical outcomes. 
C. Organ System Involvement 
Only one study to date compares outcomes in patients stratified by 
organ system involvement at the time of diagnosis. Kraemer et al.^ (1977) 
studied 204 patients retrospectively who enrolled in the Berne Clinic between 
1956 and 1976. They did not specify the sex of patients nor the average 
duration of follow-up. The patients were divided into five groups based 
on symptoms present at the time of diagnosis. The groups consisted of: 
(I) Patients diagnosed because of a positive family history. Some of these 
were diagnosed in the first months of life because they were born into 
families with members known to have cystic fibrosis. Others were diagnosed 
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at a later age after the diagnosis of an affected sibling; (II) Patients 
with gastrointestinal symptoms without clinical or radiological evidence 
of lung disease; (III) Patients with both gastrointestinal and pulmonary 
disease; (IV) Patients with predominantly pulmonary symptoms; and (V) 
Patients with meconium ileus at birth necessitating surgery. The mean age 
of diagnosis was 3.3 months for patients in group (I), 16.3 months for group 
(II), 27.5 months for group (III), 21.1 for group (IV), and just days for 
patients with meconium ileus (V). 
The authors constructed curves of cumulative survival rates calculated 
from the day of diagnosis. They did not, however, indicate the number of 
deaths among the 204 patients. These curves depict five and ten year 
survival rates as follows: 
Age 5 yr. 10 yr. 
Group Presentation N (%) At Dx Survival Survival 
I positive family 15 (7) 3.3 88% 70% 
history months 
II meconium ileus 37 (18) days 15% 10% 
III gastrointestinal 32 (16) 16.3 83% 60% 
symptoms months 
IV g.i. and resp. 58 (29) 27.5 72% 55% 
symptoms months 
V respiratory 62 (31) 21.1 48% 32% 
symptoms months 
204 (100) 
The authors concluded that patients presenting solely with pulmonary 
symptoms have a particularly poor survival. They explained the very poor 
survival in children with surgically treated meconium ileus by implicating 
perinatal and post-operative mortality. Indeed, their data reveal that 90% 
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of the ten year mortality in this group occurred in patients less than one 
year of age. 
The results are limited by several methodological problems. The authors 
combined patients diagnosed at widely disparate secular periods. Also, 
they restricted outcomes to mortality without considering morbidity. They 
failed to stratify patients by sex or by the severity of disease at 
presentation. In addition, the statistical validity of the life table data 
cannot be evaluated critically without knowledge of the number of deaths. 
Finally, the group who came to diagnosis because of a positive family 
history (i) poses problems in the interpretation of results. The authors 
mention that some of these patients were entirely asymptomatic when diagnosed 
in the first months of age on the basis of a genetic risk known at birth. 
Others were diagnosed later on, after the recognition of an affected sibling. 
The latter group may well have had signs and symptoms attributable to cystic 
fibrosis upon diagnosis, though these disease manifestations were not 
recognized as such. Hence, the group is not homogeneous with respect to 
clinical status at diagnosis. Some may have had symptoms, other may not 
have. It would be more useful in a study of the prognostic value of clinical 
symptoms at presentation to classify as "asymptomatic" only those truly 
without symptoms and to categorize others, regardless of the impetus for 
diagnosis, according to the symptoms present at the time of diagnosis. 
Hence, the symptom classification of the European Working Group for Cystic 
Fibrosis,^ upon which the Kraemer study was based, is inappropriate for 
studies relating initial clinical features to prognosis. 
One particular finding merits especially close attention. The data 
suggest that patients with both gastrointestinal and pulmonary disease at 
■ 
37 
presentation fared better than those with pulmonary disease alone. Several 
interpretations come to mind. Differences in the secular period of diagnosis 
and the gender composition of the two groups, not examined by the authors, 
could have had an effect on clinical outcomes. One might also suspect that 
the better outcomes in patients with gastrointestinal as well as pulmonary 
symptoms was due to earlier diagnosis. However, the group with 
gastrointestinal and pulmonary symptoms was in fact diagnosed at a later 
mean age. The two groups could also differ in the severity of pulmonary 
disease at presentation, or the rate of progression of disease or both. 
The data are also consistent with the notion that the two groups represent 
distinct variants of the disease with unique presentations and outcomes. 
These hypotheses are not mutually exclusive. Suffice it to say that the 
"beneficial effect" of gastrointestinal symptoms on patients also having 
pulmonary symptoms requires more rigorous analysis. 
IV. Summary and Conclusions 
This review has examined critically the existing literature on 
relationships between clinical features present at diagnosis and subsequent 
outcomes. The findings of these studies have been evaluated and methodologic 
problems noted. The results of this literature review have guided the 
design of the present study, as shall be discussed in this concluding 
section. 
A. Evaluation of Previous Work 
While each of the studies reviewed had defects which limited the 
validity and/or interpretations of results, several conclusions can still 
be reached based upon the data presented. With respect to gender, the Stern 
groups documented a result which has been consistently reported by many 
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investigators — that gender seems not to play a role in survival until the 
teenage years when the females do markedly worse than males. While the 
study is flawed, it is fair to conclude that the effect of gender should 
be evaluated in the present study as potentially affecting outcome, 
especially in teenage years. The Stern group^ also raise the question of 
whether the natural course of cystic fibrosis is milder in blacks. Their 
study does little to clarify the issue. The present study will not be 
helpful either, as only two of the patients entered into the study are black. 
The work of Huang et al.^6 indicates that the secular period of 
diagnosis may have an independent effect on prognosis. The authors' 
conclusions cannot be accepted until other variables such as gender and age 
at diagnosis are shown to be responsible for the impressive mortality in 
the group diagnosed during the earliest time interval. However, while 
inconclusive, the results warn that the secular period of diagnosis should 
be considered as potentially influencing subsequent outcomes. The patients' 
ages at diagnosis, a variable which would seem on intuitive grounds to have 
an effect on post-diagnosis outcomes, has yet to be tested adequately. 
Certainly, the study by diSantagnese^? of a residue cohort does not resolve 
the question. This variable will be examined carefully in the present study. 
Among studies of more clinical features of the presentation, the 
interesting study of Gaskin et al.24- has the least practical value for the 
present work. The authors' analysis of patients classified according to 
fecal fat measurement has little value in the absence of this laboratory 
parameter (which is not available for patients enrolled at Yale). In fact, 
the presence of patients with loose stools in the group with normal fecal 
fat excretion indicates that the Gaskin results cannot be extended to groups 
■ 
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of patients defined by gastrointestinal symptoms in the absence of laboratory 
testing. 
The work of Stern et al.^5 on patients subgrouped according to x-ray 
score is much more valuable for the present study. This paper indicated 
that significant radiological lesions which persist through the first year 
portend poor survival rates. The issue left unresolved by these authors 
is whether their results can be ascribed to a fundamental difference in 
severity of disease among patients. The other possibility, suggested by 
the advanced age of the group with worse x-rays, is that these patients 
were simply diagnosed later in the course of the disease. Regardless of 
the explanation, the finding indicates that patients with advanced pulmonary 
disease at diagnosis have lower survival at discreet intervals after 
diagnosis. 
Finally, the paper of Kraeraer et al.^ most clearly approximates the 
intent of the present work. These authors also documented that the presence 
of pulmonary symptoms at presentation was associated with worse survival. 
The study also points to gastrointestinal disease as conferring a 
"beneficial" effect on the survival of patients presenting with pulmonary 
disease. The reproducibility and explanation of this interesting result 
remain to be established. The present study shall examine this finding. 
The Kraemer study examines only mortality with no consideration of morbidity. 
Hence, no study to date has analyzed associations between presenting symptom 




Bo Methodological Defects to be Minimized 
Several methodological problems were identified in this review with 
the intent of avoiding them in the present study. First, the variables 
known or suspected to have an effect on prognosis must be controlled for. 
These potentially predictive factors include gender, secular period of 
diagnosis, age at diagnosis, severity of pulmonary disease, and other organ 
system involvement. In addition, the group of patients studied must be an 
inception cohort followed since diagnosis rather than a residue cohort 
assembled at a later point in time. The criteria for categorizing patients 
must be sensible and explicitly stated. For example, the group in Kraemer's 
study defined as having a positive family history does not necessarily share 
the same clinical manifestations (or lack of them) at diagnosis and hence 
would be inappropriate for the present study. 
Finally, outcome events should be clinically relevant and studied at 
suitable intervals. Restricting the study to survival eliminates 
consideration of morbidity status which is critically important to patients, 
physicians, and families. The present study will consider a wider range 





This chapter presents the major results of the study. Raw data are 
arranged in tables located at the end of the chapter. The results shall 
be explained in the following sections with emphasis on those findings which 
are either particularly germane to the central issues of the study or 
discrepant with previously reported data. 
Two distinct cohorts of patients have been studied. The first includes 
89 patients who enrolled between 1966 and 1978 and have thus been followed 
at least five years but less than ten years. This cohort shall be referred 
to as the "five year" group. The second cohort, the "ten year" group, is 
comprised of 55 patients enrolled between 1966 and 1973. These patients 
were followed for at least ten years. Although the ten year cohort is a 
subset of the five year group, it is important to recognize that differences 
could potentially exist in the compositions of the two groups and in their 
clinical outcomes. Hence, results obtained from study of the five year 
cohort do not necessarily apply to the ten year group and vice versa. For 
these reasons, the two groups will be discussed and analyzed separately. 
II. Results of the Five Year Cohort 
A. Description of the Cohort 
1. Demographic features: Table I presents demographic features 
of the five year cohort, including gender, race, the number of affected 
siblings, age at zero time, and the secular period of diagnosis. Half the 
patients were female and almost all (98%) were white. The mean age at zero 
time was 32 months (+ standard deviation of 49) and the median age was 13 
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months (range 1-250). The discrepancy between mean and median values 
suggests that as in other series^ the age at zero time of patients in this 
cohort generally clustered between one month and two years, with the tail 
of the distribution stretching out to 20 years. Note in Table I that 
patients were enrolled at a rather constant number from 1966-1978, six to 
eight patients per year. 
2. Select clinical features at zero time: We determined the 
prevalence at zero time of several clinical features which we suspected to 
be associated with distinct clinical outcomes. This suspicion was prompted 
both by the advice of clinicians and by reported studies.^2 The features 
included co-morbidity, clubbing, and throat culture results. Results are 
presented in Table II. Of the 89 patients, only six had one of the listed 
co-morbid diseases; 14 had moderate to severe clubbing; and 11 grew out 
pseudomonas aeruginosa. The throat culture results must be interpreted 
with caution, as throat specimens do not ideally reflect sputum flora.29 
3. Symptoms at zero time: Since the analysis is based largely 
on the particular symptoms present at enrollment, we examined the 
distribution of respiratory and gastrointestinal symptoms in the cohort. 
The results are presented in Table III. We suspected that a division of 
the patients with respiratory symptoms into two groups defined by the 
anatomic site of pathology might reveal prognostic distinctions. Hence, 
respiratory symptoms are subgrouped into "alveolar" and "upper airway" 
categories. Patients presenting with acute pneumonitis or with at least 
two prior episodes of pneumonia were categorized as "alveolar". Patients 
without alveolar disease were categorized as "upper airway", and typically 
presented with histories of cough, wheezing, or at least two episodes of 
' 
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bronchitis. Patients with alveolar disease could have had symptoms referable 
to the upper airway as well. 
Patients with gastrointestinal disease were also subgrouped. It has 
been recognized that patients with meconium ileus generally have worse 
outcomes than patients with steatorrhea.^ Among 14 patients with meconium 
ileusj those with peritonitis or requiring resection have been reported to 
do worse than patients without these complications.1^ Hence, we noted the 
frequency of patients who fell into three groups: Meconium ileus with 
resection peritonitis (5); meconium ileus without these complications 
(9); and gastrointestinal disease other than meconium ileus (65). The 
latter group shall be referred to simply as "steatorrhea" since this symptom 
is present in all the patients in the group. All but ten of the 89 patients 
had gastrointestinal symptoms at referral to the clinic, "*031 withoat 
meconium ileus. Recall that meconium ileus may be under-represented in our 
study, as patients with meconium ileus who die at birth are not enrolled 
in the clinic and therefore are not included. 
4. Clusters of symptoms at zero time: A major goal of the study 
was to analyze constellations of zero time findings, not just isolated 
symptoms. Therefore, patients were stratified into five groups defined by 
the clusters of symptoms present at zero time. The distribution of patients 
into these five groups is presented in Table IV. Only two patients were 
diagnosed on the basis of a positive family history and found to have no 
symptoms at zero time. These patients were grouped under "family history, 
asymptomatic". Four other patients were diagnosed on the basis of a positive 
family history but were noted to have other symptoms as well. These patients 
were grouped according to the symptoms present at the time of enrollment. 
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As noted in the literature, patients diagnoed on the basis of a positive 
family history have been lumped together in other series.^ A quarter of 
the patients had isolated steatorrhea with no respiratory disease at 
presentation. Eight of 89 had isolated respiratory disease with no 
gastrointestinal involvement. It should be noted that these patients 
presenting with involvement of just one organ system often went on to develop 
combined respiratory and gastrointestinal disease after the time of 
enrollment. 
Table IV also lists the mean ages at zero time for patients in the 
groups defined by symptoms clusters. (In each case the median ages are 
quite similar to the means.) Patients with meconium ileus were enrolled 
by two months of age, and those with isolated steatorrhea were enrolled by 
an average age of just a year and a half. In contrast, patients with 
combined respiratory and gastrointestinal disease were enrolled at an 
average of three and a half years of age, and those with respiratory disease 
alone at six years of age. 
5. Interval between birth and the onset of respiratory symptoms: 
Upon the advice of several clinicians, we sought associations between the 
interval from birth to the onset of respiratory symptoms and subsequent 
clinical outcomes. Table V displays the distribution of patients into 
groups defined by these intervals. Of the 49 patients with respiratory 
disease at zero time, 21 had onset of respiratory disease after a year of 
age. Some of the patients with no respiratory symptoms at zero time may 
well have developed respiratory disease by three or twelve months of age 
but were enrolled earlier. The data simply indicate that at the time of 
enrollment these patients had no respiratory disease. 
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B. Profile of Clinical Status at Zero Time and Follow-up 
To provide a baseline of comparison for the analysis section, a profile 
of clinical outcomes for the entire cohort has been presented in Table VI. 
Interestingly, the number of patients with "excellent" scores actually 
increased over five years, from 34 to 38. Eighteen of the 38 patients with 
"excellent" scores at five years did not have "excellent" scores at 
enrollment and thus improved in clinical category over five years. The 
median total Shwachman score rose slightly from 88 to 89. As indicated by 
the table, just 25 of 89 patients (28%) deteriorated in clinical category 
over five years while 64 of 89 (72%) were stable. Of the latter, 42 remained 
in the same category while 22 actually improved in clinical category. These 
data indicate that after five years, the cohort had relatively stable scores 
with a substantial number of patients actually improving. It must be noted, 
however, that the number of patients in the "terminal" category increased 
from zero at entry to five at follow-up, with four of these representing 
deaths. The survival rate was 96%. Hence, despite the overall improvement 
in the cohort, some patients deteriorated substantially. 
C. Analysis 
The overall goal of this analysis is to identify associations between 
clinical features apparent at zero time and subsequent clinical courses. 
Outcomes have been measured in terms of changes in clinical category relative 
to a baseline zero time status. To make the change in status more meaningful, 
we have presented the clinical scores at zero time as well as the subsequent 
changes in clinical category. This analysis section has been organized so 
as to clearly distinguish between features associated with poor scores at 
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zero time and those associated with distinct changes in status over follow™ 
up intervals. 
1. Clinical features associated with poor baseline status but not 
associated with distinctive changes in clinical category: 
a.) o Clubbing: The data in Table VII indicate that patients 
with mild or moderate clubbing had proportionally fewer "excellent" scores 
at zero time than patients with no evidence of clubbing. Furthermore, 25% 
of patients with moderate to severe clubbing had "poor" scores compared to 
1% among the rest of the cohort. Hence, clubbing denotes a poor clinical 
status when patients are first enrolled in the clinic. However, as evidenced 
by the table, clubbing does not predict distinctive differences in the 
clinical course after five years. 
b). Pseudomonas culture results: Similar to clubbing, positive 
throat cultures for pseudomonas were associated with proportionally fewer 
"excellent" and more "poor" scores than in the rest of the cohort. Again, 
however, the five year follow-up data revealed that positive cultures were 
not associated with distinctive changes in clinical category. 
2. Clinical features associated with distinctive changes in 
clinical category after five years, but not with distinctive scores at zero 
time: 
a). Co-morbidity: It should be noted that only six patients 
in the cohort had co-morbid disease at presentation. At zero time both 
patients with co-morbidity and those without co-morbidity had comparable 
clinical scores. However, after five years of follow-up, the six patients 
with co-morbidity had greater deterioration in clinical category than the 
rest of the cohort. Because of the small number of patients with co- 
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morbidity, the result is not statistically significant (P > .10). (Note 
that P values are two tailed in this study). Therefore3 the prognostic 
effect of co-morbidity at five years is unclear. 
3. Clinical features grouped according to organ system 
involvement: Outcomes in the four principal groups of patients defined by 
organ system involvement are displayed in Table IX-A. The fifth group, 
comprised of patients diagnosed on the basis of a positive family history 
and found to be asymptomatic, consisted of just two individuals. Because 
this group was so small, it was excluded from the analysis. The courses 
of these two patients were typical of the group as a whole. One had zero 
time and five year scores of 90 and 85, respectively. The other had scores 
of 94 and 89. 
The association between organ system involvement and five year outcomes 
(Table IX) was statistically significant (X^ = 7.8; P = .05). Analysis of 
the four principal groups indicates that patients presenting with 
steatorrhea only had the most stable clinical courses at five year follow¬ 
up, with just two of 22 (8%) deteriorating in clinical category. In fact, 
while 11 patients in this group had "excellent" scores at zero time, 17 had 
excellent scores at five years. This observation indicates that, with some 
frequency, the status of patients with steatorrhea can be expected to improve 
over the first five years of follow-up. Patients with gastrointestinal and 
respiratory disease had the next best outcomes, with 29 of 41 (71%) stable 
over five years. It should be noted, however, that these patients have the 
poorest scores at enrollment with only 9 of 41 (22%) in the "excellent" 
category and four (10%) with "poor" scores at zero time. Patients with 
meconium ileus had third best clinical outcomes with seven of 14 (50%) 
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stable. Interestingly, the presence or absence of peritonitis and resection 
did not affect the results. Finally, patients presenting with isolated 
respiratory disease had the best zero time scores but the most deterioration 
at five year follow-up, with four of eight (50%) dropping in clinical 
category. With so few patients in the group, the result is not statistically 
persuasive; hence, the actual prognostic significance of the poor outcomes 
in patients with isolated respiratory disease is difficult to assess from 
our data. 
A multivariate analysis was performed to determine whether the strong 
association between organ system involvement and subsequent outcomes 
persisted when potentially confounding variables were held constant. The 
SAS multivariate program was used. Our results revealed that at five years 
the association remained statistically significant, even when gender, 
clubbing, and co-morbidity were added to the multiple regression. 
In general, the data reveal that the 49 patients with respiratory 
disease had worse post-zero time courses than patients who presented with 
gastrointestinal disease. We sought clinical features which could separate 
these patients with respiratory disease into prognostically distinct 
subgroups. The presence vs. absence of gastrointestinal diseases did not 
satisfactorily differentiate the patients because the group with isolated 
respiratory disease numbered just eight, too few for statistically 
meaningful analysis. Based on the advice of several clinicians, we employed 
the following features to distinguish among patients with respiratory 
disease: The anatomic site of disease, the initial chest x-ray score, the 
interval between birth and the onset of respiratory symptoms and the results 
of initial staph aureus cultures. The results of these subgroupings are 
displayed in Tables IX-B-E and are discussed below. 
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a) . Anatomic site of respiratory disease: Patients with 
respiratory symptoms were categorized in the "alveolar" group if they 
presented with pneumonitis or a history of at least two episodes of 
pneumonia, and in the "upper airway" group if they did not have alveolar 
involvement. Five year follow-up data indicate that substantially more 
patients with "alveolar" disease deteriorated than those with upper airway 
disease. Although the numbers are small and the results do not achieve 
conventional levels of statistical significance (= 1.55, P = .21), the 
clinical trend is impressive. 
b) . Initial chest x-ray score: Patients were separated into 
two groups on the basis of the chest x-ray component of their total Shwachman 
scores. As discussed in the Methods section, the x-ray score was assigned 
by the method of Brasfield et al.^3 with maximum score being 25. One group 
had x-ray scores less than or equal to 21; the other group had scores greater 
than 21. Not surprisingly, the patients with x-ray scores of 21 or less 
had much worse zero time scores. Interestingly, however, the initial x- 
ray score had no association with subsequent change in clinical status. 
Hence, the finding of a chest x-ray score of 21 or less is a marker for 
poor status at zero time but does not help to identify patients who will 
deteriorate over follow-up intervals. 
c) . Interval between birth and the onset of respiratory symptoms: 
Patients were divided into two groups defined by the interval between birth 
and the onset of respiratory symptoms. Five year follow-up data indicated 
substantially greater deterioration in the scores of patients with the onset 
of respiratory disease before three months of age in the scores of patients 
with onset of disease after three months of age. 
£ 
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d) . Staph aureus culture results: The results of initial 
cultures for staph aureus did not distinguish among the five year courses 
of patients presenting with respiratory disease. 
In sum, these sub-stratifications suggest that among patients 
presenting with respiratory disease, two zero time findings identified 
groups of children with substantially greater deterioration after five 
years. These included the presence of alveolar disease and a history of 
respiratory symptoms beginning before three months of age. The results of 
staph aureus cultures and the initial chest x-ray score were not associated 
with distinctive patterns of clinical deterioration after five years, 
although as expected the lower chest film scores were associated with worse 
zero time status. 
From the data presented thus far, three broad group of patients emerge 
with distinct five year courses: Patients presenting with steatorrhea have 
markedly stable five year courses; those with respiratory disease which was 
either alveolar and/or occurred before three months of age had distinctively 
poor outcomes; patients presenting with meconium airways and/or occurring 
after three months of age had intermediate outcomes after five years. 
e) . Activity score as measures of outcome: The preceding 
paragraphs indicate that respiratory disease was associated with poor 
outcomes. One could argue that the Shwachman score is heavily weighted 
toward respiratory disease, and therefore that the results are simply 
tautologous. In fact, we feel that the Shwachman system provides a balanced 
assessment of clinical status. Nevertheless, we have examined outcomes in 




Activity scores were used to measure the outcomes of patients in the 
four groups defined by organ system involvement at zero time. Results are 
displayed in Table IX-F. The activity categories were defined by scores 
suggested by several clinicians: Excellent = 24-25; good = 21-23; fair = 
16-20; and poor = < 15. At five years, the entire cohort had 64 stable 
outcomes defined by total Shwachman scores and 69 defined by activity score. 
Results for specific subgroups were similarly analogous (compare with Table 
IX-A). Overall, it is clear that the results obtained with total Shwachman 
scores are substantiated by this less organ specific measure of clinical 
outcome. 
4. Clinical features neither associated with distinctive zero 
time scores nor with distinctive changes in clinical course after five years 
of follow-up: Table X presents data which document that several of the 
clinical features we examined were neither associated with distinctive 
scores at zero time nor with distinctive courses after five years. These 
features included the initial total Shwachman score, the secular period of 
enrollment, and the age at zero time. The finding that the initial total 
Shwachman score was not related to subsequent clinical course is crucial 
to this study. The result indicates clearly that patients destined to 
deteriorate fastest are not necessarily those that look worse at enrollment. 
The study shows that clinical features such as organ system involvement are 
much more powerful indicators of subsequent clinical course. 
III. Results of the Ten Year Cohort 
To re-emphasize a point made in the beginning of the Results section, 
the "ten year" cohort of 55 patients is distinct from the "five year" cohort 
of 89 patients. In this section the composition of the ten year cohort will 
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be discussed briefly with emphasis on distinctions between this group and 
the five year cohort. Results obtained from analysis of the ten year cohort 
shall be presented as well. 
A. Description of the Cohort 
Pertinent demographic characteristics of the cohort are displayed in 
Table XX. Females outnumbered males (29 to 26) whereas in the five year 
cohort there were 44 females and 45 males. The distribution of ages at 
zero time was quite similar to that in the five year cohort. 
The prevalence of co-morbidity and clubbing at zero time along with 
initial untoat culture results are displayed in Table XXI. All six of the 
patients in the five year cohort who had co-morbidity were enrolled before 
1973 and thus were included in the ten year cohort as well. Hence, there 
is proportionally more co-morbidity in the ten year cohort. The proportion 
of patients with actual nailbed swelling (moderate to severe clubbing) is 
slightly lower in the ten year cohort than in the five year group. The same 
is true of positive cultures for pseudomonas at zero time, while the 
proportion of patients with positive cultures for staph was actually higher 
in the ten year group. In general, with the exception of co-morbidity, the 
composition of the two cohorts did not differ substantially. 
Table XXIX displays the symptoms at zero time in the ten year cohort. 
The two groups were similarly composed with respect to respiratory and 
gastrointestinal symptoms. The representation of patients in groups defined 
by clusters of symptoms was similar in the two cohorts as well, as evidenced 
by the data in Table XXV. Table XV displays the interval from birth to the 
onset of respiratory symptoms for the patients in the cohort enrolled before 
1973. The data indicate that the two cohorts were similar, with minor 
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differences. For example, 22 of 55 (40%) patients in the ten year cohort 
reported onset of respiratory symptoms before one year of age, compared 
with 27 of 89 (30%) of the five year cohort. 
B. Profile of Clinical Status at Follow-up 
Table XVI provides a profile of clinical outcomes for the ten year 
cohort. The zero time scores of the group enrolled before 1973 were similar 
to those of the larger cohort (compare with Table VI). However, after ten 
years of follow-up, the number of patients with excellent scores decreased 
by a third, while 14 patients, or a quarter of the cohort, had poor or 
terminal scores. Five of these represented deaths. The ten year survival 
rate was 91%. The extent of clinical deterioration is also indicated in 
Table XVI which shows that 25 of 55 (45%) patients in the cohort had clinical 
deterioration after ten year. 
IV. Analysis 
A. Clinical Features Associated With Distinctive Clinica 1 Outcomes 
at Ten Year Follow-up 
Analysis of gender revealed that females had markedly greater 
deterioration in scores than males after ten years of follow-up (Table XVII- 
A). While the result is not statistically significant (P = .15) the trend 
is impressive. This finding that females deteriorate at around ten years 
after diagnosis is consistent with previously reported data. Table XVII- 
B reveals that positive cultures for staph aureus were associated with 
significant deterioration in clinical status after ten year (X^ =4.9, P < 
.05). Recall that in the five year cohort, positive cultures for staph 
were neither associated with distinct zero time scores nor with distinct 
five year follow-up courses. 
|0 
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B. Clinical Features Associated With Distinctive Outcomes at Zero 
Time and at Ten Year Follow-up 
1. Clubbing: In the five year cohort, clubbing was associated 
with poor zero time scores but not with distinctive outcomes after five 
years of follow-up. In contrast, the data in Table XVIII-A suggest that 
the presence of clubbing, especially moderate to severe, was associated 
with deterioration in scores after ten years. The result was not 
statistically significant (X2 = 2.4, P = .10). Two observations cast doubt 
on the importance of the clinical trend noted. First, the number of patients 
in the ten year cohort is small. Furthermore, comparison with Table VII 
reveals that the clubbed patients in the ten year cohort are 
disproportionately represented by patients who had already deteriorated by 
five years. 
2. Organ system involvement: The ten year outcomes of patients 
stratified by organ system involvement are displayed in Table XVIII. The 
association between organ system involvement and ten year outcomes was not 
statistically significant (X2 - 4.9; P = 0.18). However, the clinical trend 
is impressive and is similar to the results of the five year group. Once 
again, patients with steatorrhea only had the most stable courses, with ten 
of 14 (71%) having stable outcomes after ten years. Patients with combined 
gastrointestinal and respiratory disease had the next best outcomes with 
16 of 27 (59%) stable after ten years. Patients with meconium ileus and 
those with isolated respiratory disease at zero time had the worst ten year 
courses, with only around 30% of patients in each group stable. It should 
be noted, however, that the size of both groups is small. As was noted in 
< 
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the five year cohort, the presence of peritonitis or resection had no bearing 
on the outcomes of patients with meconium ileus. 
Multivariate analysis showed that the impressive though not 
statistically significantly relationship between organ system involvement 
and ten year course remained impressive when such potentially confounding 
factors as gender, co-morbidity, and clubbing were entered into the analysis. 
As in the five year analysis, we have sub-stratified patients in the 
ten year cohort who presented with respiratory disease. The data reveal 
that the anatomic site of pathology did not differentiate patients in the 
ten year cohort into prognostically distinct groups. However, it should 
be noted that the cohort includes only eight patients with alveolar disease. 
The initial chest x-ray score had no bearing on the clinical course after 
ten years of follow-up. In contrast, both onset of respiratory symptoms 
before three months of age and a positive initial culture for staph aureus 
were associated with significantly greater deterioration in clinical status 
after ten years. 
An interesting finding emerges when patients presenting with 
respiratory disease are stratified by gender. Of the 15 males in the ten 
year cohort who presented with respiratory symptoms, nine (69%) had stable 
courses after ten years. In contrast, of 20 females, only nine (45%) had 
stable ten year courses. Hence, females with respiratory disease had more 
deterioration over ten years than the males. While the numbers are not 
statistically significant, they are impressive. This pattern was not 
evidence at five years in the five year cohort. The result is consistent 
with previously reported claims that females deteriorate faster than males 
in the teen age years.^4 
' 
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Another result also aids in understanding why females appeared to fare 
worse than males in the cohort. It turns out that ten of 14 (71%) patients 
presenting with steatorrhea were males. Males and females in the group 
fared equally well. In contrast, 20 of 30 (61%) patients with respiratory 
disease were females. While females with respiratory disease clearly did 
worse than males, some of the difference in outcome between males and females 
in the cohort must be attributed to the disproportionate representation of 
males in the prognostically favorable group with steatorrhea only. 
In sum, as in the five year cohort, three groups can be defined with 
distinct outcomes after ten years. Patients with steatorrhea only in general 
do well. Patients with respiratory disease do worse. Subgroups of patients 
presenting with respiratory disease who have particularly poor outcomes 
include females, patients with positive initial cultures for staph aureus, 
and patients with early onset of respiratory disease. These results differ 
from those obtained at five years in the five year cohort in that a positive 
culture for staph and female gender had no association with distinctive 
five year outcomes in the five year cohort. 
3. Clinical features not associated with distinct outcomes at 
zero time nor at ten year follow-up: The age at zero time and the initial 
total Shwachman score were not associated with distinctive outcomes at ten 
years of follow-up. Those features had no bearing on outcomes in the five 
year cohort either. Co-morbidity was not associated with distinctive ten 
year outcomes, although in the five year cohort co-morbidity was associated 
with deterioration in clinical course. The discrepancy could be due at 





Demographic Characteristics at Zero Time (n=89) 
Charact eristic N (%) 
Gender 
Male 45 (51) 








Number of Siblings with Cystic Fibrosis 
None 
One 








3 months 23 (26) 
3 to 12 months 19 (21) 
1 to 3 years 23 (26) 
3 to 7 years 15 (17) 
7 to 10 years 4 (4) 
10 years 5 (6) 
Secular Period of Enrollment 
1966 - 1969 
1970 - 1972 
1973 - 1975 








Select Clinical Features at Zero Time (N=89) 
Clinical Feature N (%) 
Co-morbidity 
None 83 
Prematurity (4 weeks pre-dates) 3 
Neonatal Sepsis (includes one 3 
case of respiratory distress synd) 
Clubbing 
Absent 69 (77) 
Mild (erythema) 8 (9) 
Moderate to severe 12 (14) 
(nail bed swelling) 




















Symptoms at Zero Time (N=89) 
Symptoms N M 
Respiratory 
Alveolar* 17 (19) 
Upper airway, without alveolar+ 32 (36) 
None 40 (45) 
Gastrointestinal 
Meconium ileus 
Without resection or peritonitis 9 (10) 
With resection and/or peritonitis 5 (6) 
Steatorrhea^ 65 (73) 
None - 10 (ID 
* "Alveolar" includes history of two or more episodes of pneumonia 
or acute pneumonitis at zero time. 
+ "Upper airway" includes history of chronic cough, wheezing, or 
two or more episodes of bronchitis. 
# "Steatorrhea" includes bulky, foul smelling stools; rectal 




Clusters of Symptoms at Enrollment (n=89:) 
Symptom Cluster 
Family history, asymptomatic 
Meconium ileus 
Steatorrhea 
Gastrointestinal plus Respiratory 
Respiratory only 
Age at Zero Time 
N M (months) 
2 (2) 
14 (16) 2+1 
24 (2?) 19 + 20 
41 (46) 43 + 58 




Interval from Birth to the Onset of Respiratory Symptoms (n=89) 
Interval N M 
0 to <3 months 15 (i?) 
3 to <12 months 13 (14) 
> 1 year 21 (24) 
No respiratory symptoms 





Profile of Clinical Outcomes (^=89) 
Total Shwachman Scores at Enrollment and at Five Year Follow-up 
Time Clinical Status 
Excellent Good Fair Poor Terminal* Total 
Enrollment 3^ (3&%) 44 (49%) 7 (8$) 4 (4jg) 0 (0%) 89 
Five year 38 (43^) 35 {39%) 9 (10^) 2 {2%) 5 {6%) 89 
follow-up 
*Five terminal patients at five year follow-up included 
four deaths 
Change in Clinical Category at Five Year Follow-ups 
Follow-up Stable* Deteriorating4' Total 
Five years 64 {72%) 23 {2Q%) 89 
* Stable refers to patients whose clinical category improved 
or remained the same. 





Clinical Features Associated with Distinctive Outcomes at 
Zero Time hut not with Distinctive Changes in Clinical Category (N=89) 
Clubbing 
Clubbing Clinical Status at Zero Time 
Status Excellent Good 
Absent 31 (45#) 31 (45#) 
Mild 1 (12%) 7 (88%) 
Moderate to 2 (17#) 6 (50%) 
Severe 
Totals 34 (3 m 44 (49#) 
Clubbing Five 
Status Stable 
Absent 51 (74#) 
Mild 5 (63%) 
Moderate to 8 (67#) 
Severe 
Totals 64 (72%) 
Fair Poor Terminal Totals 
6 (9#) 1 (1#) 0 (0#) 69 
0 (0#) 0 (0#) 0 (0#) 8 
1 (8#) 3 (25%) 0 {0%) 12 
7 (8%) 4 (4#) 0 (0#) 89 
Year Status 
Deteriorating Totals 
18 (26%) 69 
3 (37#) 8 
4 (33%) 12 
25 (28%) 89 





Status at Zero Time 
Fair Poor Terminal Totals 




(Q%) 2 (100#) 
(9%) 7 (64#) 
(43#) 35 (46#) 
(38#) 44 (49#) 
0 (0#) 0 (0#) 
1 (9%) 2 (18#) 
6 (8#) 2 (3#) 
7 (8#) 4 (4#) 
0 (0#) 2 
0 (0#) 11 
0 (0#) 76 
0 (0#) 89 
Culture 
Status 
Five Year Status 




2 (100#) 0 (0%) 2 
7 (64#) 4 (36%) 11 
55 (72#) 21 (28%) 76 




Clinical Features Associated with Distinctive Changes 
in Clinical Category after Five Years, but not with 




Clinical Status at Zero Time 
Good Fair Poor Terminal Totals 
Co-morbidity 2 (33%) 3 (5°%) 
Present 
Co-morbidity 32 (39%) 41 (49%) 
Absent 
Totals 34 (38%) 44 (^9%) 
1 (17%) 0 W) o (0*) 6 
6 (7%) 4 (5%) 0 (0jS) 83 












3 {50%) 3 {50%) 6 
61 (73%) 22 {27%) 83 




Clinical Features Associated with Distinctive Outcomes 
Both at Zero Time and at Five Year Follow-up (N = 8?) 
A. Organ System Involvement 
Organ Clinical Status at Zero Time 
System Excellent Good Fair Poor Terminal Tota! 
Steatorrhea 11 (46*) 11 (46%) 2 (8%) 0 (0%) 0 (0*) 14 
Gastrointest 9 (22%) 24 (59*) 4 (10%) 4 (10%) 0 (0%) 41 
and Respir 
Meconium 7 (50%) 6 (43*) 1 (7%) 0 (0*) 0 (0%) 14 
ileus 
Respiratory 5 (62%) 3 (38*) 0 (o*) 0 (0%) 0 (0*) 8 
alone 
Totals 32 07%) 44 (51%) 7 (8%) 4 (3%) 0 (0%) 87 
Organ 
System Stable 
Five Year Status 
Deteriorating Totals Deaths 
Steatorrhea 22 (92%) 2 (8%), 14 1 
Gastrointest 29 (71%) 12 (29%) 41 2 
and Respir 
Meconium 9 (64%) 5 (36*) 14 1 
ileus 
Respiratory 4 (50*) 4 (50%) 8 1 
alone 
Totals 64 (73%) 23 (26*) 87 4 
Site of Respiratory Disease 
Site Stable 
Five Year Status 
Deteriorating Totals 
Alveolar 9 (53*) 8 (47%) 17 
Upper Airway 24 (75%) 8 (25*) 32 
33 (6?%) 16 (33%) 49 Totals 
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TABLE 9, continued 
G. Initial Chest X-Ray Score 
Score 
Clinical Status at Zero Time 




less than or 2 (7%) 17 (63%) 4 (15%) 4 (15%) 0 (0%) 
=21 
greater than 12 (55%) 10 (45%) 0 {0%) 0 (0%) 0 (0%) 
21 
Totals 14 (29%) 27 (55%) 4 (8%) 4 (8%) 0 (0%) 
Five Year Status 
Score Stable Deteriorating Totals 
less than 18 (67%) 9 (33%) 27 
or =21 
greater 15 (68%) 7 (32%) 22 
than 21 
Totals 33 (67%) 16 (33%) 49 
Interval from Birth to the Onset of Respiratory Symptoms 
Five Year Status 
Interval Stable Deteriorating totals 
less than 8 (53%) 7 (47%) 15 
-3- months 
greater than 24 (73%) 9 (27%) 33 
or = 3 months 
Totals 32 {67%) 16 (33%) 48 
Results of Initial Cultures for Staph Aureus 
Five Year Status 
Results Stable Deteriorating Totals 
Positive 11 (65%) 6 (35%) 17 
Negative 22 (69%) 10 (31%) 32 
Totals 33 (67%) 16 (33%) 49 
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TABLE 9» continued 
F. Association Between Organ System Involvement and Changes in 
Activity Category over Five Years (n =* 87) 
Organ Five •, Year ■ Activity Status 
System Stable Deteriorating Total 
Steatorrhea 23 (9656) 1 W) 24 
Gastrointest 32 9 {22%) 41 
and Respir 
Meconium 10 {71%) 4 (29%) 14 
ileus 
Respiratory 4 (50%) 4 {50%) 8 
alone 
Totals 69 {79%) 18 {21%) 8? 
Stables Activity category improves or remains the same. 
Deteriorating: Activity category worsens over the interval of follow-up. 
Activity Categoriess Excellent = 24-25; Good = 21-23? Fair = 16-20; 




Clinical Features Neither Associated With Distinctive Zero 
Time Scores nor With Distinctive Changes in Clinical 
Category after Five Years(n = 89) 
A. Secular period of enrollment 
Secular Clinical Status at Zero Time 
Period Excellent Good Fair Poor Terminal Total 
1966-72 19 (42%) 22 (49%) 2 (4%) 2 (4%) 0 (0%) 45 
1973-78 15 (346) 22 (5<W) 5 (113) 2 (5%) 0 (0%) 44 
Totals 34 (38%) 44 (49%) 7 (8)6) 4 (4%) 0 (0%) 89 
Secular 
Period Stable 
Five Year Status 
Deteriorating Totals 
1966-72 31 (69%) 14 (31%) 45 
1973-78 33 (750 11 [25%) 44 
Totals 64 (72%) 25 (2856) 89 




at Zero Time 
Poor Terminal Total 
^ 3 months 12 (52#) 10 (4352) 1 (456) 0 (0%) 0 (0%) 23 
73 - 12 mon. 8 (42%) 6 (32%) 4 (21%) 1 (5%) 0 (0%) 19 
712-36 mon. 6 (26%) 17 (74%) 0 (0*) 0 (0%) 0 (0%) 23 
7 36 months 8 (3356) 11 (4656) 2 (8%) 3 (12%) 0 (0%) 24 
Totals 34 (38%) 44 (49%) 7 (8%) 4 (4%) 0 (0%) 89 
M2 Stable 
Five Year Status 
Deteriorating Totals 
£: 3 months 14 (61%) 9 (39%) 23 
7 3-12 months 13 (68)6) 6 (3252) 19 
7 12-36 months 20 (87%) 3 («) 23 
2 36 months 17 (71%) 7 (2%) 24 
Totals 64 (72%) 25 (2856) 89 

TABLE 10, continued 
69 
G. Initial Total Shwachman Score 
Five Year Status 
Score Stable 
90 - 100 (excellent) 20 (5%) 
80 - 89 (good) 35 (79%) 









Totals 64 (72%) 25 (28%) 89 
D. Gender 
Clinical Status at Zero Time 
Gender Excellent Good Fair Poor Terminal Totals 
Male 17 (38%) 21 (47%) 4 (9%) 3 (7%) 0 (0%) 45 
Female 17 (39%) 23 (52%) 3 (7%) 1 (2%) 0 (02) 44 
Totals 34 (382) 44 (49%) 7 (8%) 4 (4%) o (02) 89 
Five Year Status 
Gender Stable Deteriorating Totals 
Male 33 (73%) 12 (2?%) 4 5 
Female 31 (70%) 13 (30%) 44 
Totals 64 (72%) 25 (28$) 89 
E. Staph Aureus Results 
Culture Clinical Status at Zero Time 
Status Excellent Good Fair Poor Terminal Totals 
Not cultured 0 (0 %) 2 (100%) 0 (0 %) 0 (0%) o (Q2) 2- 
Positive 9 (35%) 12 (46%) 4 (15%) i W) o (02) 26 
Negative 25 (41%) 30 (49%) 3 (%) 1I&L o (02) 61 
Totals 34 (38%) 44 (49%) 7 (8%) 4 (Ly%) o (02) 89 
Culture Five s Year Status 
Status Stable Deteriorating Totals 
Not cultured 2 (100%) 0 (0% }) 2 
Positive 19 (73%) 7 (27%) 26 
Negative 43 (70%) 18 (30%) 61 




Demographic Features at Zero Time (N=55) 
Feature N M 
Gender 
Male 26 (47) 
Female . 29 (53) 
2. 3 months 13 (24) 
3 to <12 months 13 (24) 
1 to < 3 years 15 (27) 
3 to <7 years 9 (16) 
7 to <10 years 3 (5) 
•^.10 years 2 (4) 

TABLE 12 71 




Prematurity (4 weeks pre-dates) 3 
Neonatal Sepsis (includes one case 3 





























Symptoms at Zero Time (n=55) 
Symptom N M 
Respiratory 
Alveolar 8 (15) 
Upper Airway 23 (46) 
None 22 (40) 
Gastrointestinal 
Meconium ileus 
Without resection or peritonitis 3 (5) 
With resection or peritonitis 4 (7) 
Steatorrhea 41 (74) 




Clusters of Symptoms at Zero Time (N=55) 
Symptom Cluster N M 
Family history, asymptomatic 1 (2) 
Meconium ileus 7 (13) 
Steatorrhea 14 (25) 
Gastrointestinal and Respiratory 27 m 




Interval from Birth to the Onset of Respiratory Sympto ms 
(K-55) 
Interval N M 
0 to <3 months 12 (22) 
3 to <12 months 10 (18) 
>1 year 10 (18) 




TABLE 16 75 
Profile of Clinical Outcomes (N - 55) 
Total Shwachman Scores 
Clinical Status 
Period Excellent Good Fair Poor Terminal Total 
Zero Time 23 (42?Q 26 (4?#) 4 (7%) 2 (4#) 0 W) 55 
Ten Years 16 (29%) 19 (35^) 6 (11%) 6 (11%) 8 (15%)* 55 
* 8 terminal patients include 5 deaths 
Change in Clinical Category at Ten Year Follow-up 
Period Stable Deteriorating Totals 















Clinical Features Associated with Distinctive 
Clinical Outcomes at Ten Year Follow-up ('Na,55) 
Stable 
Ten Year Status 
Deteriorating Totals 
17 (65* *) 9 {3%) 26 
13 M) 16 (55^) 29 
30 {55%) 25 (45%) 55 
initial cultures for staph aureus 
Stable 
Ten Year Status 
Deteriorating Totals 
7 {39%) 11 (61%) 18 
22 (61%) 1^ {39%) 36 
29 (55%) 25 (^5%) 54* 




Clinical Features Associated with Distinctive Outcomes at Zero 




Absent 27 (6056) 




Totals 30 {55%) 
B. Organ System Involvement 
Organ ■ 
System Stable 




Meconium ileus 2 (296) 
Respiratory alone 2 (336) 
Totals 30 (56%) 
* one in the family history, 
C.Site of Respiratory Disease 
Site Stable 
Alveolar 4 (50%) 
Upper Airway 14 (56%) 
18 {55%) 
Ten Year Status 
Deteriorating Totals 
18 (406) 45 
3 (606) 5 
4 (806) 5 
23 W%) 55 
Ten Year Status 
Deteriorating Totals 
4 (71%) 1# 
11 W) 27 
5 (71%) 7 
4 (676) 6 
24 (446) 54* 
asymptomatic group 
Ten Year Status 
Deteriorating Totals 
4 (50%) 8 
11 (446) 25 
15 W) 33 Totals 

TABLE 18, continued 
D. Initial Chest X-Ray Score 
Ten Year Status 
Score Stable Deteriorating Totals 
less than or * 21 8 {57%) 6 (43J6) 14 
greater than 21 10 (536) 9 (Wo) 19 
Totals 18 {55%) 15 {Wo) 33 
E. Results of Initial Culture for Staph aureus 
Culture Ten Year Status 
Result Stable Deteriorating Totals 
Positive 3 (25%) 9 (75%) 12 
Negative 15 (72%) 6 (28%) 21 
Totals 18 {55%) 15 {W) 33 
F. Interval Between Birth and the Onset of Respiratory Symptoms 
Interval Stable Deteriorating Totals 
less than 3 mo• 4 (336) 8 (6?%) i 12 
greater than or 14 {67%) 7 (33%) 21 
* 3 mo. 
Totals 18 {55%) 15 (Wo) 33 
G. Gender 
Ten Year Status 
Gender Stable Deteriorating Totals 
Male 9 {69%) 4 (31J6) 13 
Female 9 (W) 11 (55%) 20 




Clinical Features not Associated with Distinctive 
Outcomes at Zero Time nor at Ten Year Follow-up (N*55) 
Age at Zero Time 
Age Stable 
Ten Year Status 
Deteriorating Totals 
< 3 months 4 (31%) 9 ((>9%) 13 
> 3 to 1.2 months 7 Wo) 6 (96%) 13 
^12 to 36 months 12 (80*) 3 (20%) 15 
> 36 months 7 (59*) 7 (50%) 14 
Totals 30 (55%) 25 (9%) 55 
Initial Total Shwachman Score 
Ten Year Status 
Score Stable Deteriorating totals 
90 - 100 10 (93%) 13 (52%) 23 
80 - 89 16 (61%) 10 (39*) 26 
t 79 4 (67%) 2 (33*) 6 
Totals 30 (5%) 25 (Wo) 55 
Co-morbidity • 
Ten Year Status 
Co-morbid Status Stable Deteriorating Totals 
Co-morbidity present 3 (596) 3 (50*) 6 
Co-morbidity absent 27 (55%) 22 (45*) 49 




This concluding chapter is divided into three sections. First, major 
findings of the study will be discussed with emphasis on the concordance 
of our results with previously reported data. It should be emphasized that 
ours is the first study of the clinical features of presentation to focus 
on morbidity outcomes. Other series have considered only mortality. While 
it is informative to check our morbidity data against previously noted 
mortality trends it should be recognized that these two outcomes are 
distinct. The second section of this chapter will discuss implications of 
our findings for clinical management and research. Finally, new direction 
will be suggested for future research on the associations between clinical 
features of presentation and subsequent outcomes. 
I. Major Findings 
A. Descriptive Data 
The patients entered into the study were generally similar in 
demographic and clinical features to those followed by other investigators. 
However, it should be noted that no other authors have examined several of 
the zero time features considered in this study such as clubbing, co¬ 
morbidity, and initial throat culture results. Only two othei aatnors nave 
subgrouped patients according to organ system involvement (Kraemer et al.^ 
who studied 204 patients in Berne, Switzerland, and Gurwitz et al.30 who 
studied 734 patients followed in Toronto). In general, the distribution 
of patients in these studies into groups defined by organ system was similar 
to the distribution in the present study. There were a few differences 
which merit discussion. Kraemer et al. reported that 7% of patients belonged 
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in the "family history" category, while the present study included just two 
patients (2%) in the "family history, asymptomatic" group. As discussed 
in the Methods sections, our criteria for classification of patients was 
based on symptom status at zero time. Hence, we included under "family 
history, asymptomatic" only those patients truly found to have no symptoms. 
In contrast, while the Kraemer study also purports to focus on symptom 
status at presentation, their classification is based on the stimulus for 
diagnosis — the family history —■ without regard for actual symptom status 
of patients in this group. We considered performing a separate analysis 
of the prognostic significance of various diagnostropic stimuli, but were 
unable to assemble sufficiently reliable data. 
The distribution of males and females into groups defined by organ 
system involvement also differed considerably in our group from previously 
reported findings. Gurwitz et al. reported on 734 patients and found that 
the numbers of males and females in groups defined by organ system were 
roughly equal. Specifically, among 121 patients presenting with steatorrhea 
only, 52% were male. Also, 52% of 515 patients with respiratory disease 
(either isolated or occurring with steatorrhea at zero time) were male. In 
contrast, we found that of 24 patients in the five year group presenting 
witn steatorrhea 5d% were male. Also, of 49 patients in our overall cohort 
presenting with respiratory disease, just 41% were male. Hence, in our 
study, the most prognostically favorable group (steatorrhea alone) was 
disproportionately represented by males, and the least prognostically 
favorable groups (respiratory disease) were disproportionately represented 
by females. Because our cohort is much smaller than the Gurwitz series, it 
' 
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is possible that our results could represent sampling artifact rather than 
a true clinical distinction. 
A final area in which our cohort differed from previously reported 
groups was the age at presentation. Kraemer et al. report that patients 
with isolated respiratory disease had an average age of 21 months at 
presentation, anu tu^oe wicu coiuDinea respiratory and gastrointestinal 
disease an average of 27 months. Corresponding values for our study were 
73 (+ 64) months for isolated respiratory symptoms and 43 (+ 58 months) for 
combined respiratory disease and steatorrhea. Several reasons can be offered 
to explain these differences. It is possible that the earlier age of 
diagnosis in the Kraemer series reflects heightened suspicion of CF on the 
part of physicians. This is unlikely in view of the fact that the Kraemer 
study includes patients diagnosed in the 1950's when the level of clinical 
suspicion of cystic fibrosis was probably lower. The difference could also 
be due to different biologic behavior of the diseases in Europe than in the 
U.S. No data exist to support this hypothesis. More likely, our series 
includes patients whose symptoms did not become severe enough to raise the 
suspicion of CF until a relatively late age. These patients might have 
been missed at an earlier secular period when the disease was regarded as 
more homogeneous in expression, with symptoms appearing in infancy. The 
significance of late manifestations of CF has been discussed in the 
literature,^ but remains poorly understood. The patients could represent 
a milder variant of CF with the manifestations remaining subclinical until 
relatively late. Alternatively, these patients could have a variant which 
is no less severe than usual but is expressed in later years. 
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Bo Mortality Data 
The survival in the five year cohort was 96%; in the ten year cohort, 
survival was 91%. These figures are comparable to survival data reported 
by the Cystic Fibrosis Foundation.^ It is striking that three out of four 
deaths in the five year group and four out of five in the ten year group 
occurred in patients presenting with respiratory disease. I~ facf , the on*3 
death in the five year cohort occurring in a patient without respirator' 
disease (he had meconium ileus) was not primarily due to CF. This patient 
had an "excellent" total Shwachman score just before death. None of the 
patients presenting with steatorrhea alone died. All but one of the deaths 
of patients presenting with respiratory disease occurred in females. There 
was no distinctive pattern in the ages at diagnosis of patients who died. 
These data are consistent with the conclusions of Kraemer et al.^ that 
steatorrhea alone is associated with the highest five and ten year survival 
rates, and that the presence of respiratory disease at presentation is 
associated with lower survival rates. 
C. Morbidity Data 
This study focused primarily on morbidity, both because death was an 
infrequent outcome event in our cohorts and because we felt changes in 
clinical status short of death are critical for patient management and 
germane to clinical research. Major findings are discussed below: 
1. Clinical features associated with poor zero time scores: These 
included positive culture for pseudomonas and the presence of clubbing. 
Our results are consistent with generally accepted descriptions of the 
progression of CF^ in which clubbing and pseudomonas colonization are felt 
to occur initially in patients with relatively poor overall status. 
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Interestingly, the patients with clubbing and pseudomonas colonization at 
zero time do not deteriorate in clinical status any faster than the rate 
of the cohort as a whole* This observation indicates that clinical markers 
of advanced disease do not necessarily signal impending deterioration. 
2. Organ system involvement: The association between organ system 
involvement and subsequent outcomes was statistically significant in the 
five year group and impressive though not significant in the ten year group. 
Multivariate analysis revealed that even when such factors as gender, co¬ 
morbidity, and the presence of clubbing were held constant, organ system 
involvement continued to be strongly associated with distinct outcomes. 
This is perhaps our most important finding. It affirms the basic hypothesis 
of the study: That patients can indeed be separated into prognostically 
distinct groups based on clinical features at presentation. Results of 
each of the groups will be discussed below. 
a). Meconium ileus: The morbidity of patients with meconium 
ileus were typical of the entire cohort both at zero time and at five years. 
In contrast, several series, including the Kraemer study, report that 
meconium ileus was associated with the worst prognosis in terms of 
mortality.^ Several reasons explain the better outcomes of patients with 
meconium ileus in our series. First, other investigators, including Kraemer 
et al., include only patients requiring surgery in their meconium ileus 
group, categorizing patients with meconium ileus relieved by gastrograffin 
enema as "gastrointestinal". Since the bulk of mortality is due to surgery, 
the Kraemer criteria select for a group more likely to have poor outcomes. 
We feel our classification is preferable because it is based on the actual 
presence or absence of intestinal obstruction rather than the success of a 
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particular therapeutic maneuver, the gastrograffin enema. Meconium ileus 
also had a more favorable prognosis in our series in part because we did 
not include patients who died in infancy of small bowel obstruction, thus 
never enrolling in the Yale clinic. This unavoidable exclusion probably 
also explains why patients with resection or peritonitis did uoc uo 
especially poorly in our series. Dire sequelae of these complication 
probably result in death before patients are enrolled in the clinic. More 
recent series have reported that patients with meconium ileus have similar 
courses to those with normal births. Authors have attributed the improved 
outcomes over the last 15 years to improvements in operative techniques, 
life support, and management.^ Hence, the Kraemer series, which included 
patients enrolled in the 1950's, spans prognostically distinct secular 
intervals. 
b). Steatorrhea: In both the five and ten year cohorts, patients 
presenting solely with steatorrhea (or related problems such as rectal 
prolapse) had considerably less morbidity than the rest of the cohort. Our 
results for morbidity are consistent with the finding of Kraemer et al. in 
which patients with steatorrhea had the lowest mortality at five and ten 
year follow-up. These results are also consistent with a widely accepted 
understanding of the significance of involvement of different organ 
systems.^ Gastrointestinal disease can be ameliorated with pancreatic 
enzymes and does not contribute to mortality or significant morbidity. 
Patients presenting with steatorrhea are treated with enzymes and become 
virtually asymptomatic until the onset of respiratory disease. Respiratory 
involvement, in contrast, progresses insidiously despite therapy. Hence, 
patients presenting with steatorrhea in a sense "wave a red flag", signalling 
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their diagnosis at a stage in their disease at which they do not have 
clinically apparent lung involvement. Whether the respiratory disease that 
ultimately develops in these patients is as severe as in patients initially 
presenting with respiratory symptoms is beyond the scope of this study. 
cj. Kespiratory disease: In general, patients with respiratory 
disease had poor outcomes at follow-up intervals. We suspected this group 
to be heterogeneous with respect to prognosis, and therefore attempted to 
identify those clinical features associated with particularly poor outcomes 
in patients presenting with respiratory disease. 
1) . Combined respiratory and gastrointestinal disease: Our 
data suggest that the presence of gastrointestinal disease is associated 
with a better prognosis than respiratory disease alone. This finding is 
consistent with the "protective" effect of gastrointestinal disease noted 
by Kraemer et al. However, there were few patients in our cohorts with 
isolated respiratory disease. Our results must therefore be interpreted 
cautiously. 
2) . Alveolar disease: Patients presenting with alveolar 
disease had especially poor outcomes after five years of follow-up. The 
anatomic site of disease has not been considered in previous studies. This 
trend was not observed at ten year follow-up; however, the number of patients 
with alveolar disease in the ten year group was small. 
3) . Onset of disease in the perinatal period: Patients with 
appearance of respiratory symptoms by three months of age had especially 
poor outcomes at five and ten years. Our data support the hypothesis that 
onset of respiratory symptoms early in infancy heralds an aggressive course. 
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4) . Gender: We observed that females with respiratory disease 
have similar status to males at enrollment and five year follow-up, but 
deteriorate markedly by ten year follow-up. Other investigators have noted 
that females have worse survival than males in the teen age years. Several 
hypotheses have been offered to explain these results, including poor 
compliance with therapy among females in the teen age years, and diminished 
strength among females in clearing secretions.30 We also observed that the 
disproportionately large number of females presenting with respiratory 
disease also contributed to the worse overall outcomes among females in the 
cohort. 
5) . Staph aureus colonization: Patients colonized with staph 
at zero time were indistinguishable from the rest of the cohort at zero 
time and at five year follow-up, but had poor ten year outcomes. No other 
series has offered data on the prognostic effect of initial cultures for 
staph. 
3. Pertinent negative findings: One possible consideration is 
that patients with the worst initial total Shwachman scores would deteriorate 
fastest. If that were the case, clinical features might have little further 
prognostic value. However, our data document clearly that the initial total 
score is of no value in predicting the clinical course. The clinical 
features discussed throughout this study provide much better indicators of 
prognosis than simple assessment of overall status by Shwachman score at 
zero time. 
The age of patients in the cohort at zero time had no clear relation 
to subsequent outcomes either. As discussed in the Literature Review, no 
. 
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previous study had adequately examined the prognostic significance of the 
age at zero time. 
Finally, the secular period of enrollment had no prognostic value 
either. This finding is not surprising. The eligibility criteria for tile 
study were designed in part to assure that the same basic therapeutic 
measures were available to all patients. 
II. Implications for Clinical Management 
From the descriptive and analytic findings of this study, we can 
delineate several profiles of patients with distinct clinical features at 
presentation and subsequent outcomes. This section will present four brief 
case histories of patients actually included in our study who typify these 
profiles. The cases will include one patient with steatorrhea, another 
with meconium ileus, and two with respiratory disease -- one with a 
relatively benign outcome and the other with an aggressive course. These 
cases do not encompass all of the features discussed in the study. For 
example, patients with isolated respiratory disease are not represented, 
as there were just eight such individuals in the study. 
A. Steatorrhea 
D.B. is a ten year old white male who was the product of a normal 
delivery to a family with no known history of cystic fibrosis. By one month 
of age his parents reported the stools to be foul-smelling, bulky, and 
greasy. After an episode of rectal prolapse at five months of age, he was 
sweat tested, and diagnosed as having CF. He had no clubbing at that time, 
and throat cultures revealed normal flora. Total Shwachman score at 
enrollment to the Yale clinic was 83 with a nutrition score of 18 and chest 
x-ray of 25. At five year follow-up, the patient's overall status improved 
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with a total score of 94. His chest film was still entirely normal (25) 
and with pancreatic enzyme supplementation, his nutrition score had improved 
to 23. By ten year follow-up the patient still had only minimal compromise 
in ms daily activities. Total Shwachman score was 93 although the chest 
x-ray slipped to 22. An interesting addition to D.B.'s history is that he 
developed Coombs negative hemolytic anemia shortly after diagnosis, a rare 
complication of CF felt to be due to deficiency of Vitamin E. 
Aside from the anemia, D.B.'s history is quite typical of patients 
presenting with steatorrhea. These children are often diagnosed at less 
than a year of age with normal chest x-rays. Their overall status improves 
with enzyme therapy and does not deteriorate until respiratory disease 
ensues. The recent change in chest x-ray score suggests that D.B. may begin 
to show progressive deterioration. 
B. Meconium Ileus 
T.G. is a nine year old white male born with meconium ileus relieved 
surgically but without resection. Sweat test in the neonatal period was 
positive. The patient had no respiratory symptoms at enrolment and throat 
cultures showed normal flora. Total score was 87 with a nutrition score 
of 18. By five years of follow-up, the patient was in excellent condition 
with an x-ray score of 24, a nutrition score of 23, and a total score of 
97. Recently, at nine year follow-up, he had a chronic cough, mild clubbing, 
colonization with staph aureus, and chest film of 22. Total score had 
slipped to 93. 
T.G. typifies the child with meconium ileus who survives the neonatal 
period and has a relatively mild course. Currently, these children do no 
worse than patients with CF with normal births. Like D.B., T.G. has just 
. 
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recently shown respiratory involvement and can be expected to deteriorate 
slowly. 
C. Respiratory Disease 
L. N. is a ten year old female who was the product of a normal delivery. 
By six months of age, the mother reported a history of foul, bulky stools, 
and chronic cough to the pediatrician. When these symptoms persisted at 
nine months of age, the pediatrician ordered a sweat test which was positive. 
There was no history of pneumonia, no clubbing, and initial chest x-ray 
score was 25. Throat culture was positive for staphlococcus aureus. Total 
Shwachman was 91. By five years of follow-up, the patient had developed a 
productive cough, pseudomonas colonization, and moderate clubbing. Chest 
film score was 19 and total score was 84. At ten years the chest film 
dropped to 18 and total score to 83. The patient had been admitted several 
times for management of pseudomonas colonization and infection. 
Steatorrhea led to the diagnosis in L.N. 's case, the respiratory disease 
being mild at enrollment. As the respiratory disease worsened, her overall 
status fell as well. However, it is noteworthy that by ten years of age 
she still had a "good" score. Hence, L.N. represents a child with combined 
gastrointestinal and respiratory disease at presentation, but with a 
relatively good outcome at ten years. 
M. G. was born in 1969, the normal female product of a family with no 
history of CF. She had a chronic cough from birth and steatorrhea beginning 
around six months of age. By two years of age, these symptoms persisted 
and her local pediatrician performed a sweat test which was positive. At 
enrollment, she had no clubbing, negative throat cultures, and no pneumonia. 
Chest film was 24 and total score was 89. By five year follow-up, she had 
' 
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recently shown respiratory involvement and can be expected to deteriorate 
slowly. 
Co Respiratory Disease 
L. N. is a ten year old female who was the product of a normal delivery. 
By six months of age, the mother reported a history of foul, bulky stools, 
and chronic cough to the pediatrician. When these symptoms persisted at 
nine months of age, the pediatrician ordered a sweat test which was positive. 
There was no history of pneumonia, no clubbing, and initial chest x-ray 
score was 25. Throat culture was positive for staphlococcus aureus. Total 
Shwachman was 91. By five years of follow-up, the patient had developed a 
productive cough, pseudomonas colonization, and moderate clubbing. Chest 
film score was 19 and total score was 84. At ten years the chest film 
dropped to 18 and total score to 83. The patient had been admitted several 
times for management of pseudomonas colonization and infection. 
Steatorrhea led to the diagnosis in L.N. 's case, the respiratory disease 
being mild at enrollment. As the respiratory disease worsened, her overall 
status fell as aowever, ic is notewortny tnat by ten years of age 
she still had a "good" score. Hence, L.N. represents a child with combined 
gastrointestinal and respiratory disease at presentation, but with a 
relatively good outcome at ten years. 
M. G. was born in 1969, the normal female product of a family with no 
history of CF. She had a chronic cough from birth and steatorrhea beginning 
around six months of age. By two years of age, these symptoms persisted 
and her local pediatrician performed a sweat test which was positive. At 
enrollment, she had no clubbing, negative throat cultures, and no pneumonia. 
Chest film was 24 and total score was 89. By five year follow-up, she had 
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pseudomonas colonization and a chest film of 20. Total score was still 89, 
however, as her nutritional status had improved from enrollment. By ten 
years her respiratory ux&ease uaa worsened marKediy, ner chest x-ray being 
15 and total score 20. She had recently been admitted for anti-pseudomonal 
therapy. She died at twelve year of age. 
M.G.'s history reflects the aggressive course that the disease often 
takes in patients (especially females) with onset of respiratory symptoms 
early in infancy. 
While these vignettes do not touch upon all of the issues discussed 
in this study, the histories do support the principal conclusions. First, 
it is important to note that except for M.G., these patients generally had 
good scores ten years after enrollment. This phenomenon is representative 
of the cohort as a whole after ten years. The challenge for clinicians is 
to identify those patients who will deteriorate fastest. Clearly, the 
initial total scores are of no help, as D.B. and T.G. had the lowest initial 
scores but the mildest subsequent clinical courses. The mode of presentation 
is more helpful: The first two cases reflect that overall status of patients 
without respiratory disease often improves with pancreatic enzyme 
supplementation and does not deteriorate substantially until the onset of 
respiratory disease. In contrast, the third and fourth cases reflect the 
finding that patients with respiratory disease at the onset deteriorate 
faster. This distinction in the clinical significance of respiratory and 
gastrointestinal involvement is the central theme emerging from histories 
of the patients in our study. 
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III. Implications for Clinical Research 
The recognition of prognostically distinct groups of patients also has 
implications for clinical research. For example, a clinical trial of 
therapeutic interventions would be biased if one group of subjects were 
represented disproportionately by patients with particularly favorable or 
unfavorable prognoses. Hence, investigators should assure that experimental 
cohorts have even representation of patients from prognostically distinct 
groups. Furthermore, particular interventions may only be effective or 
appropriate in select subgroups of patients. Therefore, in studying the 
efficacy of such measures, investigators should stratify their subjects 
into these distinct subgroups. 
IV. Directions for Future Research 
This study raises several unanswered questions which could be explored 
by further clinical research. Four broad areas for future study will be 
outlined briefly in this section. 
A. The Prognostic Effect of Features .'jot Aae4udLtij avaiuacea rn 
This Study 
Because some of the subgroups were quite small, we were unable to 
evaluate four features with statistical persuasiveness. These included co- 
morbid disease; the distinction between isolated respiratory disease and 
combined respiratory and gastrointestinal disease; the outcomes of patients 
truly found to be asymptomatic at presentation; and the prognostic effect 
of alveolar disease at ten year follow-up. Study of a larger series might 




Bo Diagnostic Stimulus vs. Symptoms Present at Presentation 
It was apparent that the events leading to sweat test differed among 
patients who had very similar symptom status at zero time. It would be 
interesting to study the relationship between diagnostic stimulus and 
subsequent outcomes among patients with similar clinical presentations. 
Such an analysis would refine the present study by considering the 
variability in identification of patients with the likely diagnosis of 
cystic fibrosis. 
C. Early vs. Late Onset of Respiratory Disease 
We have shown that patients with onset of respiratory disease in the 
perinatal period have worse outcomes. It would be interesting to determine 
whether patients with onset after three months of age have less aggressive 
disease, or whether it is equally aggressive but simply arises later. In 
addition, it would be useful to evaluate the onset of respiratory disease 
at later points in the clinical course as we did in this study at three 
months of age. 
D. Correlation With Pulmonary Function Tests 
Currently most clinicians follow the progress of patients with cystic 
fibrosis with pulmonary function tests. However, as pointed out earlier, 
patients cannot perform PFT's until around six years of age. Hence, these 
tests cannot be used to characterize zero time status. Clinicians are left 
to describe the presentations in term of clinical features considered in 
this study. It would be useful, therefore, to correlate these clinical 
features at zero time with subsequent pulmonary function test parameters. 
The results would help clinicians integrate the clinical trends we have 
outlined into their conventional manner of following older patients. This 
proposal poses the larger question, already the focus of clinical research 





1. Anderson, D.H., "Cystic fibrosis of the pancreas and its relation 
to celiac disease; clinical and pathological study," American 
Journal of Diseases of Children 56:344-99i (1938). 
2. Wood, R.E., "Cystic fibrosis; Diagnosis, treatment and prognosis," 
Southern Medical Journal 72:189-202, (1979) • 
3. A Report of the Patient Registry, Cystic Fibrosis Foundation, 
Volume 1978, Rockville, MdT (1978) . 
4. Doershuk, C., and Boat, T., "Cystic fibrosis," in Nelson Textbook 
of Pediatrics, 12th edition, edited by R.E. Behrman and V.C. Vaughan III, 
W.B. Saunders, Phila-delphia, (1983) • 
5. Stern, R.C., et al, "Course of cystic fibrosis in black patients," 
Journal of Pediatrics 89:417-19 (1976). 
6. Shwachman, H., "The heterogeneity of cystic fibrosis," Birth Defects 
Original Article Series, vol. VIII, No. 2:102-1-7 (1972"}"^ 
7. di'Santagnese, R.A. and Davis, P.B., "Recent reeearch in cystic 
fibrosis," Monog. Paediatr. 10:66-76 (1979). 
8. Gibson, L.E. and Cooke, R.E., "A test for concentration of electrolytes 
in sweat in cystic fibrosis of the pancreas using pilocarpine ionto- . 
phoresis," Pediatrics 23"545-49 (1959)- 
9. Kraemer, R., Hadorn, B., Rossi, E., "Classification at time of 
diagnosis and subsequent survival in children with cystic fibrosis," 
Helv. Paediat. Acta 32:107-114 (1977)• 
10. Cystic Fibrosis: A Disease in Search of Ideas, volume 2, by the U.S. 
Department of Health, Education, and Welfare, U.S. Government 
Printing Office (1978). 
11. Anderson, C.M., et al Cystic Fibrosis: Manual of Diagnosis and 
Management, Blackwell Scientific, Oxford (1976). 
12. Chang, N., Levison, H. et al, "An evaluation of nightly mist tent 
therapy for patients with cystic fibrosis," Amer. Review of 
Respiratory Disease 107:672-75 (1973). 
13. Matthews, L.W. et al, "A therapeutic regimen for patients with cystic 
fibrosis," Journal of Pediatrics 655^-75 (1964). 
14. Shwachman, H., "Long term study of one hundred five patients with 
cystic fibrosis," AMA Journal of Diseases of Children, 96:6-15 (1958). 

96 
15* George, L., "Life tables for cystic fibrosis," Archives Disease 
in Childhood 46;139 (1971). 
16. Kollberg, H., "Incidence and survival curves of cystic fibrosis 
in Sweden," Acta Paediatr. Scand. 71*197-202 (1982)., 
17. Shwachman, H. et al, "Report of 130 patients diagnosed under three 
months of age over a 20 year period," Pediatrics 46:335-^3 (1970). 
18. Orenstein, D. et al, "The effect of early diagnosis and treatment 
in cystic fibrosis," American Journal Diseases Child 131*973-75 (1977). 
19o "Cystic Fibrosis Program Report, 1981-1982," Yale-New Haven 
Cystic Fibrosis Clinic (1982). 
20. Estimate of the clinic director. No data are available in the 
published literature to document the number of patients diagnosed 
with cystic fibrosis, but not seen at a specialized center. 
21. Dolan, T., unpublished data 
22. May, J.R., Herrick, N.C., Thompson, D., "Bacterial infection in 
cystic fibrosis, Archives Disease Child 47*908-13 (1972). 
23. Brasfield, D. et al, "The chest radiograph in cystic fibrosis: 
A new scoring system," Pediatrics 63*24-29 (1979). 
24. Gaskin, K. et al, "Improved respiratory prognosis in patients with 
cj^tic fibrosis with normal fat absorption, " Journal Pediatrics, 
100:857-62 (1982). 
25. Stern, R.C. et al, "Course of cystic fibrosis in 95 patients," 
Journal Pediatrics 89:406-11 (1976). 
26. Huang, N. et al, "Survival of patients with cystic fibrosis," 
American Journal Disease Cjiild 120:289-95 (1970). 
27. di'Santagnese, P., and Davis, P., "Cystic fibrosis in adults," 
American Journal of Medicine 66:121-131 (1979). 
28. di'Santagnese, P. and Talamo, R., "Pathogenesis and physiopathology 
of cystic fibrosis of the pancreas," New England Journal of 
Medicine,277*1287-94 (1967). 
29. Harrison's Principles of Internal Medicine, tenth edition, edited by 
Petersdorf R. et al, McGraw Hill, New York, 1983. p. 846. 
30. Gurwitz, D., et al, "Perspectives in cystic fibrosis," 
Pediatric Clinics of North America 26:603-615 (1979). 
31. Taussig, L., et al, "A new prognositc scoring system and clinical 





A. Data Extraction Form 
B. Data Coding Form 
C. Summary of Shwachman Clinical Scoring System 
D. Summary of Brasfield X-Ray Scoring System 

Appendix A 
Date of Extraction: _/_/ Hospital Unit No. 98 
Extractor: Study No. 
DATA COLLECTION FORM — CF STUDY 
I. Demographic Information 
Name * Birth Date / / Gender Phone 
Parents' Name Address 
Parents' Occupations: Father: Mother: 
Referring M.D. Town Phone 
Number of Children in Family at Time of Enrollment__ 
Birth Order of Children ___ 
II. Pre-Existing Conditions 
A. Relative with CF: Yes _____ No __ If yes, relationship _ 
Date Dx _/ J Age at Dx __ Age at Death __ 
Principal Organ System at Dx  
B. Co-Morbidity: Yes _ No _ If yes, please describe below: 
Disease Yes No Description and Dates 



















99 2 - 
Clinlcal Itinerary of Principal Illness 
A. Earl jest Signs and Symptoms — list dates and describe; 
JL 
B. Hospitalization for Principal Illness — list dates and diagnoses; 
1.___ « ___ 
2 o __ 
3„ ____  
4 „ _  
Co Signal Events Raising Suspicion of CF ■—• list dates, symptoms, signs, labs, 
and diagnostic imaging 
D. Iatrotropic Stimulus for Sveat Testing; 
E. Sveat Test; Yes _ No __ 
Date _/_/_ Location_Result 
F. CF Dx Dates: 
1. Initial Suspicion 
2. Plan to Sweat Test 
3. Sweat Test 
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G. Hospitalizations for IV Antibiotic Therapy 
Date Duration Treatment/Drugs ; Administered 
L / / 
2. / 1 
3. / / 
4. / / 
5. / J 
H. Other Hospitalizations 
Date « Duration Indication Treatment 
1. / / 
... — .. — 
2. / / 
I» Weight Gain 
Time Wt. % Time Wt. % 
Subsequent 
Follow-Up Dates Wt. % 
Birth Diagnosis 
i yr Enrollment 
5 yrs 2 yr fellow 
10 yrs 5 yr fellow 
Appearance of Symptoms and Signs 
Date of Date of 














Meconium Ileus (HI) 
Complication of MI-1ist 
Meconium Plug Syndrome 
Wt. <5th % 
Steatorrhea 

- 4 - 
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Date of Date of 














Date of Death __/_/_ 
Date of Loss to Follow-Up _/_/_ Reason 





(1) Unit Number 
][][][][][][] 
1 2 3 4 5 6 7 
(7) Age At ZT 
[][][] Months 
18 19 20 
(10) // Sibs With CF At ZT 
[ 1 
29 
(13) Neonatal Sepsis 
[ ] 1= Yes 
32 2 = No 
(16) Onset Sx To ZT 
[][][] Same as (15) 
37 38 39 
(2) Card Number 
[ 3 
8 
(8) Date Of ZT 
[ 3 [ ] Month [ ] [ 1 Year 
21 22 23 24 
PRE-ZT CO-MORBIDITY: 
(11) Prematurity 
(14) Other Co-morbidity 
[3 0 = None 
33 1 = g-e 
2 = Bilary Artesia 
3 = Hypothyroid 
4 =Meconium aspiration 
5 =Meconium plug 
6 =Hirshprungs 
7 =Aliac disease 
(17) Pre ZT Hosp. (Resp.) 
[ 3 o=o 
40 1 = 1 
Etc. 
(3) Date of Birth 
[ 3 [ 3 Month [ ] [ ] Year 
9 10 11 12 
(6) Race 
[ ] 1= Black 
17 2 - White 
3 = Hispanic 
(9) Date of Dx 
[ 3 [ 3 Month [ ] [ ] Y 
25 26 27 28 
(12) RDS 
(15) Birth To Onset of Sx 
[][][]# Months 
34 35 36 enter 999 if 
uncertain; 
888 if asx at 
ZT 
(18) Pre-ZT Hosp. (GI) 
[ 3 0=0 
41 1 = 1 
Etc. 
(4) ID Number (5) Gender 
[ 3 [ 3 [ 3 [ 3 1= Male 
13 14 15 16 2 = Female 
[ ] 1 = Yes 
30 2 = No 
[ 3 
31 
1 = Yes 
2 = No 

j) Pre-ZT Hosp. (Resp. & GI) (20) Resp» Sx At ZT 10?21) Resp. Sx At ZT 
[ ] 0=0 
42 1 = 1 
Etc. 
[ ] 0 = None [ ] Same as (20) 
43 1= Recus. Pneumonia 44 
2= Recur. Bronchitis 
3 = chronic Cough 
4 = Wheezing 
5 = Acute Pneumonitis 
6 = Resp. Sx, n.b.s. 
9=Unknown, Uncertain 
;) Resp. Sx At ZT (23) GI Sx At ZT (24) GI Sx At ZT 
] Same 
) 
as (20) [ ] 0 = None 
46 1= Steatorrhea 
2 = Rectal Prolapse * 1 
3 = Recurrent Prolapse 
4 = Abdominal Pain 
5 = Poor Weight Gain 
6 = Mecileus 
7 = GI, WOS 
8 = Constipation 
9 = Unknown 
[ ] 
47 
Same as (46) 
) GI Sx At ZT (26) Other Sx At ZT (27) Other Sx At ZT 
I Same as (46) [ ] 0= None [ ] Same as (26) 
4 49 1 = Hx Coombs - Anemia 50 
2= Hx Hyponatremic Dehydration 
3 = Hx Hypoproteinemic Edema 
4 = Biliary Cirrhosis 
5 = Nasal Polyps 
6 = Femoral Hernias 
7 = Increased LFT’s 
8 = Glucose intolerance 
(28) Signal Event Leading to Dx 
[ ] 01= Hx, ASX 
52 02 = Mec. Ileus, No Surgery 
03 = Mec. Ileus With Surgery; No Resection 
04 = Mec. Ileus With Resection 
05 = Mec. Ileus With Peritonitis 
06 = Steatorrhea 
07 = Rectal Prolapse; Hx Steatorrhea 
08= Steatorrhea In View Of Resp. Hx 
09 = Abdominal Pain 
10=Nucococle of Appendix 
11= FTT Inpatient 
12= FTT Outpatient 
13 = Recurrent Bronchitis 
14 = Recurrent Pneumonia 
15= Acute Resp. Disease;Positive GI 
16= No Acute Event; Pos. GI & Resp. Hx 
17 = Cholestatic Jaundice 
18 = Hyponatremic Dehydration 
19=Hypoproteinemic Edema 
20= Coombs - Anemia 
21= Fam. Hx, With Sx 
22= Recurrent cough 
23 - Recurrent wheeze 
9) Diagnostic Setting 
[ ] 1= Ambulatory 
53 2 = Hospital 
(30) Clubbing At ZT 
[ ] 0 = Absent 
54 1 = Mild 
2 = Moderate 
3 = Severe 
(31) Cultured At ZT? 
[ ] 1 = Yes 
55 2 = No 

52) Pseudomonas At ZT (33) Staph at ZT (34) Hemophilus At ZT 
] 0 = Not Cultured [ ] 0 = Not Cultured [ 1 0 = Not Cultured 
56 1 = Yes 57 1 =Yes 58 1 = Yes 
2 = No 2 = No 2 = No 
55) Weight At Zt (36) Height At Zt (37) Wt For Age At ZT 
[ ] [ ] //Kg [ ] [ ] [ ] //cm [ 3 1 = 0-5% 5=>50-75% 
59 60 61 62 63 64 2 = >5-10% 6=>75-90% 
3 = >10-25% 7= >90% 
4 = >25-50% 9 = Unknown 
58) Ht For Age At ZT (39) Wt For Ht At ZT (40) Pseudomonas Post ZT 
[ ] Same as (37) [ 3 Same as (37) [ 3 [ 3 Years Post ZT Until 
65 66 67 68 + Culture 
(Ent er 00 if + At ZT; 99 If Never 
88 if not cultured 
(41) Staph Post ZT (42) Hemophilus Post ZT (43) I.V. Cleanouts 
] [ ] Same as (40) 
9 70 
[ ] [ ] Same As (40) 
71 72 
[ ] Total // [ ] [ ] Years AFter ZT 
73 74 75 of First Admit 
(99 If None) 
44) G.I. Hosps. Post ZT (45) Unit Number (46) Card // 
otal // [ ] [ ] Years After [][][][][][][] 
77 78 ZT of 1st 1 2 3 4 5 6 7 
Admit 
(99 if none) 
[2] 
8 
47) Co-morbidity Post ZT 
[ ] 1= Yes 
9 
[50) Status At 2 Years 
[ ] 1= Dead 
13 2 = Alive 
3 = LTFU 
(48) Type Of Co-morbidity 
[ ] 0 = None 
10 1= Arrhythmia 
2 = Cholangitis 
(51) Status At 5 Years 
[ ] 1= Dead 
14 2 = Alive 
(49) Year Of Death 
[ ] [ ] 00 = Alive 
11 12 
(52) Status At 10 Years 
[ ] 1= Dead 
15 2 = A1 iv e 
3 - LTFU 
4= Followed <10 Years 

- 4 - 
105 
(0 Year Of Last FU (54) Status At Last FU (55) Interval Between ZT & Death 
[ ] [ ] [ ] 1 = Dead [ ] [ 1 [ ] # Months 
16 17 18 19 20 21 Enter 888 If Alive 
Enter 999 If Uncertain 
(56) Interval Between Onset Sx (57) Interval Between Dx 
And Death And Death 
[ ] [ ] [ ] Same As (55) [ ] [ ] [ ] Same As (55) 
22 23 24 25 26 27 
ZT 2 Yrs 5 Yrs 10 Yrs Recent 
(8) Total Shwachman [][][] [][][] [ ] [ ] [ ] [][][] [][][] 
28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 
'9) Activity [ ] [ ] MM [ 1 [ 1 [ ] [ ] [ ] [ ] 
43 44 45 46 47 48 49 50 51 52 
0) Physical Exam t ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] 
53 54 55 56 57 58 59 60 61 62 
(1) Nutrition [ ] [ ] [ ] [ ] [ ] [ 1 [ ] [ ] [ ] [ ] 
63 64 65 66 67 68 69 70 71 72 
(62) Unit # (63) Card // 
[][][][][][][] [3] 
1 2 3 4 5 6 7 8 
>4) X-Ray Total [ ] [ 1 MM [ ] [ ] [ ] [ ] [ ] [ I 
9 10 11 12 13 14 15 16 17 18 
>5) Air Trapping [ 1 [ ] [ 1 [ ] [ ] 
19 20 21 22 23 
)6) Bronchial Cuffing [ ] [ ] [ ] [ ] [ ] 
24 25 26 27 28 
VI) Small Lesions [ ] [ 1 [ ] [ ] [ ] 
29 30 31 32 33 
38) Large Lesions [ ] [ ] [ 1 [ ] [ ] 
34 35 36 37 38 
39) Overall Severity [ ] [ ] [ ] [ ] [ ] 
39 40 41 42 43 
(Enter 0 If Patient Has Not Been Followed For the Length of Time Indicated. Round 
.5 Values To Lowest Whole Number.) 
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(70) Birth To Onset Of Resp Sx (71) Birth To Onset Of G.I. Sx 
[ ] 1= 0-1 Month 
44 2 = 1-3 Months 
[ ] Same As In (44) 
45 
3 = 3-6 Months 
4 = 6-12 Months 
5 = 1-3 Years 
6 = 3-5 Years 
7 = 5-10 Years 
8= Greater Than 10 Years 
9 = Unknown 
0= No Sx Before ZT 
(72) Birth To Onset Of Other Sx (73) Cause Of Death 
[ ] Same As In (44) [ ] 1= Resp Decomp 
46 47 2 = G.I. Decomp 
3 = Accident 
4 = Metabolic Imbalance 




Grading* Points General Activity Physical Exam Nutrition X-Ray Findings 
Excellent 25 
(86-100) 
Full normal activity No abnormal¬ 
ities 
Weight and height Clear lung 
above 25th %ile fields 





20 Tires at end of day Rare cough 
Good school No clubbing 
attendance Clear lungs 
Wt and Ht at Slight broncho 
15th to 25th %ile vascular 
Bulky stools markings and 
Fair muscle mass emphysema 
Mild 
(56-70) 
15 Exertional fatigue 



















































*Note that our clnical categories differ from those described by Shwachman. 
e.g. excellent = 90-100 in our study. We chose to categorize according to 
the clinic directors assessment of which numerical intervals corresponded to 




Summary of Brasfield X-Ray Scoring System 
Abnormality Comments Scoring (demerit points) 
Air trapping Generalized over-distension 0 - absent 
manifest as sternal bowing, 1 
depressed diaphragms, or thoracic 2 increasing 




Parrallel,branching or "end-on" 
circular densities with 
thickening of bronchial wall 






lesions Multiple, discrete small 
rounded densities, 0.5cm in 
diameter or larger 





Large lesions Segmental or lobar atelectasis 0 








General severity Impression of overall severity 
of x-ray changes 





5 = complications 
(e.g. pneumothorax, 
cardiac enlargement) 






YALE MEDICAL LIBRARY 
Manuscript Theses 
Unpublished theses submitted for the Master’s and Doctor’s degrees and 
deposited in the Yale Medical Library are to be used only with due regard to the 
rights of the authors. Bibliographical references may be noted, but passages 
must not be copied without permission of the authors, and without proper credit 
being given in subsequent written or published work. 
This thesis by has been 
used by the following persons, whose signatures attest their acceptance of the 
above restrictions. 
NAME AND ADDRESS DATE 

